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1. INTRODUCTION 
Pharmaceutical dosage form design and product development requires a wide 
range of expertise and background knowledge. The working process starts from 
a disease target identification, active substance identification following with 
pharmacological/toxicological investigations, preformulation, final formulation 
development, and clinical trials in order to prove the safety and efficacy of the 
final product. Regulatory guidelines are intended for the pharmaceutical 
industry to support the product development and to assure the quality, safety 
and efficacy issues (CDER/FDA, 2015; CDER/FDA, 2007; ICH 2015). For 
example, extensive dissolution tests and stability studies are crucial for a 
successful product development and a drug product approval process.  
Oral administration remains the main route for drug delivery. It is a simple, 
rapid, convenient and painless way of drug administration for a wide range of 
dosage forms, thus making it the most attracting one for the patients and 
pharmaceutical industry. It is generally known that aqueous solubility and 
gastrointestinal (GI) permeability are the key parameters controlling the rate and 
extent of drug absorption, although the onset of drug action is also affected by 
the complexation on target receptors. European Pharmacopoeia classifies the 
solubility without any solvent specification in terms of quantification, a soluble 
compound requires less than 1 ml or up to 30 ml of a solvent to be dissolved 
(“very soluble” / “freely soluble” / “soluble”), and compounds that need over 
30 ml or more than 10 000 ml of a solvent have been termed as „sparingly 
soluble” / “slightly soluble” / “very slightly soluble” / “practically insoluble” (Ph. 
Eur. 9.0). Based on US Food and Drug Administration (FDA) guideline and 
classification, a drug is considered highly soluble when the highest dose 
strength is soluble in 250 mL or less of aqueous medium over the pH range of 
1 to 6.8 (CDER/FDA, 2015). European Medicine Agency defines highly water-
soluble drugs as drugs with a dose/solubility volume of less than or equal to 
250 ml over a pH range of 1.2 to 6.8. Drugs not fulfilling these requirements are 
considered poorly water-soluble (European Medicines Agency, 2000). 
According to the Biopharmaceutics Classification System (BCS), drugs are 
categorized into the following four groups based on the abovementioned two 
parameters: high solubility-high permeability (BCS I); poor solubility-high 
permeability (BCS II); high solubility-poor permeability (BCS III); poor 
solubility-poor permeability (BCS IV) (Amidon et al., 1995). According to the 
literature, only 5% of new active substances can be placed in BCS I while 90% 
of such drugs are considered as poorly water-soluble (PWS) (BCS II and IV) 
(Williams et al., 2016). It has been reported that over 75% of drugs under the 
development or in the product pipeline are classified as PWS (Di et al., 2009). 
The development of advanced formulations, new excipients and manufacturing 
methods will foster the understanding of how to improve the aqueous solubility 
and dissolution rate of drugs, and hence the bioavailability of PWS drugs. 
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In the present PhD thesis, the principal hypothesis was that amorphous solid 
dispersions (SDs) prepared with Soluplus® (SOL) and xylitol (XYL) and using 
different methods of preparation improve the dissolution rate and stabilize an 
amorphous PWS drug (indomethacin, IND as a model drug). SOL is a novel 
amphiphilic graft co-polymer which was originally designed for hot-melt 
extrusion (BASF, 2010). XYL is a small molecule sugar polyol, which has just 
recently found its position as a pharmaceutical excipient. Quench cooling (QC) 
of the melt is a common approach along with the solvent evaporation method 
for SDs preparation. In addition to QC, melt-electrospinning (MES) can be 
regarded as another modification of traditional melting/fusion method for SD 
preparation. In the present study, MES was studied as a novel approach to 
prepare the advanced drug delivery systems for PWS drugs. Physicochemical 
characteristics and drug release from QC mixtures with different carriers 
SOL/XYL were investigated. The melt-electrospun fibers (MSFs) with their 
unique properties were investigated, and the key question was, whether they 
could accelerate the dissolution rate of such drug and improve its physico-
chemical stability within a novel dosage form. We showed that the produced 
MSFs of a PWS drug (IND) were physically stable and presented immediate 
drug release. 
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2. LITERATURE REVIEW 
2.1. Challenges of poorly water-soluble drugs 
The adoption of new formulation strategies for PWS drugs are currently of great 
interest, since the majority of new drug candidates emerging from the drug 
development pipeline are PWS compounds (Brough and Williams, 2013). The 
major reasons behind this phenomenon are an increased application of combi-
natory chemistry, desire to achieve site-specific drug targeting, and high-
throughput screening in non-aqueous media (Lipinski, 2000). According to 
Takagi et al. (2006), among top 200 drug products (parenteral and modified 
release excluded) 30–40% were composed of an active substance(s) categorized 
as practically insoluble (solubility <0.1 mg/ml). This leads to a number of 
concerns, since such drugs have extremely low absorption in the GI tract 
resulting in low oral bioavailability, and hence a limited therapeutic effect. To 
mitigate this problem, most often a time-consuming and expensive formulation 
development is needed. Promising formulation approaches are the formation of 
salts, cyclodextrins, polymorphs and co-crystal, particle size reduction, and use 
of surfactants, co-solvents and lipid based formulations (Brough and Williams, 
2013; Gursoy and Benita, 2004; Hörter and Dressman, 1997; Jermain et al., 
2018; Williams et al., 2016). As a separate technological approach, solid 
dispersions (SD) can be prepared, and to date SDs have found uses in many 
commercially marketed products (Table 2) and will be discussed in more detail 
in the following chapters. Herein, in this thesis, SDs prepared via melting/ 
co-fusion showed its potential as a means for improving the aqueous solubility 
of PWS drugs. 
 
 
2.1.1. Theory of solubility/dissolution rate 
Aqueous solubility of active pharmaceutical ingredient (API) is a key parameter 
to be resolved in the pharmaceutical product development and in the subsequent 
preclinical and clinical settings. The solubility of API is affected by the inter-
molecular and intramolecular forces, lipophilicity, ion charges, and H-bonding 
with a dissolution medium (Lipinski, 2000). The dissolution rate is driven by 
the concentration gradient between the concentration on the particle surface and 
concentration in the bulk medium (Williams et al., 2013). Solubility and dis-
solution rate relationship is characterized by Noyes-Whitney (1987) equation 
(Eq. 1):  
 
 ௗCௗ୲ =
஽஺
௛  (ܥݏ − ܥݐ) (Eq. 1) 
 
where dC/dt is the dissolution rate, D the diffusion coefficent, A the surface 
area, h the diffusion layer thickness, Cs the saturation solubility of the drug in 
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medium and Ct the amount of drug in solution at time t (Noyes and Whitney, 
1897). 
According to Eq. 1, PWS drugs have low solubility (Cs), and consequently, 
this results in a low concentration gradient (Cs-Ct) and low dissolution rate. 
Furthermore, PWS drugs possess a poor in vitro/ in vivo correlation and these 
drugs are also prone to interact with food (Gu et al., 2007).  
 
 
2.1.2. Effect of solid-state form on the solubility/dissolution  
behavior of drug 
The API may exists in crystalline (usually with different crystal modifications) 
or amorphous form. In crystalline solids, molecules have a three dimensional 
(3D) long-range order and are packed very tightly, with a repeating unit cell. 
The strong intermolecular interactions within the crystal lattice result in the 
reduced mobility of the molecules and higher physical stability (lower 
solubility, dissolution and disintegration rate) (Zhang et al., 2004). Crystalline 
APIs can exist as polymorphs, solvates or hydrates. Futhermore, the co-crystals 
and salts of APIs may be prepared. Polymorphic systems are usually divided 
into two groups, enantiotropic and monotropic (Burger and Ramberger, 1979a). 
In enantiotropic systems, reversible transitions can occur between polymorphs 
at defined transition temperature below melting point (Tm). In monotropic 
systems, no reversible transitions between polymorphs can take place below 
melting point (e.g., indomethacin, IND). It is also known that the most stable 
polymorph at specified environmental conditions has higher density values 
(Burger and Ramberger, 1979b). Polymorphs show also different physico-
chemical properties such as chemical and physical stability, flowability, hygro-
scopicity and tableting behavior, solubility, and dissolution rate (Haleblian and 
McCrone, 1969). The human studies have shown that polymorphism affects the 
bioavailability, oral drug absorption and hence drug therapy efficacy (Singhal 
and Curatolo, 2004). Common ways for preparing the amorphous form of API 
are solvent and fusion/melting methods, which will be discussed in more 
detailed in the following sub-chapters. Amorphous materials lack highly 
ordered three dimensional (3D) crystal structure, thus these materials possess 
lower intermolecular interactions. Due to a higher free energy level, the API in 
an amorphous form has higher apparent solubility, but it is less stable (solution 
or solid-state mediated) resulting in the recrystallization of less soluble crystal 
form (Burger & Ramberger 1979b). The present stability changes are solution 
or solid state mediated. The risk is especially high with narrow therapeutic 
window APIs (e.g., carbamazepine) which undergo transformation during the 
dissolution to a metastable form (from anhydrate to hydrate), compromising 
solubility, dissolution rate and therapeutic efficiency (Edwards et al., 2001; 
Murphy et al., 2002). In case of carbamazepine this may lead to epilepsy 
treatment failures. Three mechanisms are involved in solution mediated 
transformations namely (1) dissolution of metastable form, (2) molecular 
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rearrangement to stable phase, (3) and subsequent growth of stable phase 
(Murphy et al., 2002). Solid state mediated transformation may occur during the 
manufacturing or storage. The mechanical stress (grinding, compression) 
applied to crystal structure, producing amorphous regions results in improved 
dissolution rate (Mosharraf and Nyström, 1995). Amorphous solids prepared by 
different methods will have different glass transition temperature (Tg), 
relaxation times and kinetics affecting their chemical and physical stability 
(Shalaev and Zografi, 2002). In order to avoid the unwanted solid-state phase 
transformation of amorphous solid, the addition of stabilizing carrier is often 
used to prevent or limit the nuclei formation and subsequent crystal growth in 
the system (Brough and Williams, 2013). Amorphous solids formulated with or 
without stabilizing carrier differ from each other in terms of physical (incl. 
mechanical) and chemical properties (Vippagunta et al., 2001). Therefore, it is 
paramount to select the most suitable solid state form for the pharmaceutical 
product development. 
 
 
2.1.3. Methods to improve drug solubility and dissolution rate 
One of the common and most effective ways to improve the solubility of PWS 
APIs is a salt formation for weak bases and weak acids. However, this is quite 
challenging since only 20–30% of new chemical entities are able to form a salt 
(Serajudin & Pupipeddi, 2008). The complex formation with cyclodextrins 
(CD) is another option with hydrophilic outer exterior and hydrophobic inner 
cavity (Stella and He, 2008). Cyclic structure of CD allows to entrap the drug 
inside the CD cavity forming water-soluble inclusion complexes. Today, drug-
CD complexes can be found in over 35 marketed pharmaceutical products 
(Davis and Brewster, 2004; de Oliveira Makson et al., 2015). The aqueous 
solubility and dissolution of APIs are also dependent on polymorphism, and 
there is a considerable difference between the solubility and dissolution rate of 
different polymorphs. Tawashi (1968) reported that the dissolution rate of 
aspirin polymorphic form II was 50% faster compared to form I. Pudipeddi & 
Serajuddin (2005) studied the solubility ratios of total 55 compounds (actually 
81, due to several forms for some compounds) and revealed that an average 
solubility ratio for different polymorphs was 1.7 (Pudipeddi and Serajuddin, 
2005). However, it would be incorrect to draw conclusions regarding the 
bioavailability of such compounds. Solubility ratio of amorphous form is usually 
higher (e.g., glibenclamide 14) (Hancock and Parks, 2000). Co-crystal formation 
is another approach towards improved solubility and dissolution rate of APIs, 
where a target API is combined with a coformer crystal by non-covalent and 
non-ionic forces. Co-crystals have shown solubility advantage over crystalline 
polymorphs and similar or above the amorphous form (Good and Rodriguez-
Hornedo, 2009).  
Particle size reduction of APIs leads to increased surface area available for 
solvation and dissolution. Particles can be obtained in micron and nano sized 
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range. Nanoparticles have several fold higher specific surface area compared to 
micron sized particles, thus leading to even higher dissolution rates. It has been 
shown that over 80% ibuprofen nanocrystals prepared by comminution dis-
solved within only 2 min (Plakkot et al., 2011). Surfactants are able to 
solubilize PWS APIs through micelle formation, which improves wetting and 
are commonly used in (nano)suspensions for stabilizing purpose (Williams et 
al., 2013). 
In co-solvent systems organic solvents such as ethanol, glycerol, propylene 
glycol, polyethylene glycol 300/400, dimethyl sulfoxide, dimethylacetamide are 
mostly used (Williams et al., 2013). Organic solvents are increasing the 
solubility of PWS APIs by reducing the polarity of the bulk solvent. Co-
solvents are commonly combined with surfactants in self-emulsifying formu-
lations, but toxicity issues and risk of drug precipitation upon dilution limits the 
use of such systems (Lukyanov and Torchilin, 2004; Williams et al., 2016). The 
application of more safer lipid systems comes from the dietary lipids, which are 
well absorbed across the GI tract. Lipid based formulations (LBF) are good 
choice for lipophilic PWS drugs with dissolution rate as a limiting step. In most 
cases, LBFs are combinations of surfactants, co-solvents and natural or 
synthetic oils. After mixing with GI fluids and dilution effect, LBFs form oil-in-
water (o/w) emulsions or microemulsions, which are readily absorbed from a GI 
tract (Gursoy and Benita, 2004). Recent advancement in co-amorphous systems, 
where two small molecules combined together (ratios 1:1, 1:2, 2:1), has resulted 
in increased apparent solubility, dissolution rate and provided good physical 
stability. Such approach could be an alternative to polymer based amorphous 
SD (Korhonen et al., 2017). 
All these strategies are aimed (1) to reduce the intermolecular forces in 
solid state, (2) to increase the lipophilicity and solubilization, and (3) to increase 
the surface area which will be in contact with the solvent. However, the 
influence of the manufacturing method on the physicochemical stability of drug 
should be assessed to avoid the risks related with the thermal degradation, 
formation of chemical decomposition products, and polymorphic or other 
unwanted solid state transformations during processing (Janssens et al., 2010; 
Jermain et al., 2018; Van Den Mooter, 2012; Williams et al., 2013). 
 
 
2.2. Solid dispersions 
Solid dispersion (SD) is a broad term describing drug dispersion in a carrier 
matrix, where usually a hydrophobic drug is dispersed in a hydrophilic carrier 
(sugar, polymer). There are different ways how SDs have been classified. 
Firstly, SDs have been classified based on material type, physical state of 
ingredients and miscibility (Brough and Williams, 2013; C. Brown et al., 2014; 
Van Den Mooter, 2012). These types are crystalline SD, amorphous SD, and 
amorphous solid solution (Figure 1). The crystalline SD is a multiphase-
immiscible system, with crystalline and separate carrier phase. Amorphous SD 
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is also a multiphase system with discrete amorphous drug distributed in an 
amorphous carrier manifesting in multiple glass transitions (Tg). Amorphous 
solid solution is a miscible, one-phase system, where the drug is homo-
geneously dispersed within the carrier phase. In such systems, differential 
scanning calorimetry (DSC) shows only single Tg. 
Fig. 1. Solid dispersion classification based on phases and different states. Key: Tg – 
glass transition temperature (modified from Williams et al., 2016). 
 
Secondly, Thommes et al (2011, 2012) have classified SDs into subtypes based 
on the solid-state form of the drug/carrier (crystalline/amorphous) and number 
of phases (Table 1). In one-phase systems, the drug is molecularly dispersed 
within the carrier and both components exist in the amorphous phase (or co-
crystal) (Thommes, 2012; Thommes et al., 2011). Such formulations are widely 
considered as the most desired ones for PWS drugs. The application of one-
phase systems, however, is challenging due to the limitations related to the drug 
loading and manufacturing. Furthermore, the dissolution of one-phase SDs may 
be even worse compared to a pure drug, if the intermolecular binding between 
the drug and matrix material is too strong. For example, impaired dissolution 
has been reported recently with one-phase IND and SOL containing SDs 
(Surwase et al., 2015). With these factors in mind, one can also consider two-
phase systems. In two-phase systems, the components can be present as 
independent crystalline and/or crystalline/amorphous phases. Thommes et al. 
(2011) prepared a crystalline suspension by using a hot-melt extrusion (HME) 
method, where crystalline drug was physically mixed with crystalline sugar. 
Interestingly, such HME crystalline suspension is like a physical mixture with 
an exception that it has significantly improved dissolution properties compared 
to that of a conventional physical mixture (Thommes et al., 2011; Thommes, 
2012). 
Those amorphous SDs where the drug is in an amorphous form have higher 
apparent solubility and faster dissolution rate compared to their crystalline 
counterpart (Di et al., 2009; Hasegawa et al., 2005; Newman et al., 2012). Due 
to the high tendency of recrystallization associated with thermodynamically 
 
Crystalline Solid Dispersion  Amorphous Solid Dispersion Amorphous Solid Solution
9 multi-phase system 
(discrete crystalline drug & carrier phase)
9 Tg for polymeric carrier
9 melting endotherm of crystalline
drug of crystalline carrier
9 multi-phase system
(discrete amorphous drug & carrier phase)
9 multiple Tg observed
9 one-phase system
(drug molecularly & 
homogeneously dispersed 
within the carrier)
9 single Tg observed
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unstable amorphous drugs, proper carrier molecules with desired functionality 
are of utmost importance. The key mechanisms by which carrier materials 
provide physical stabilization for amorphous drug within SD include (1) the 
reduction in molecular mobility via increasing local viscosity, (2) intermole-
cular interactions between the drug and carrier, and (3) the prevention of a 
crystal nucleation (Hancock and Zografi, 1997; Marsac et al., 2008a; Van Den 
Mooter, 2012) 
 
Table 1. Classification of pharmaceutical solid dispersions, SDs (I) (modified from the 
classification system introduced by Thommes, 2012). 
 Solid 
Solution 
Glassy 
Solid 
Solution 
Compound
Complex 
Formation 
Solid 
Crystal 
Suspen- 
sion 
Eutectic 
Mixture
Amorphous 
Precipitation
Glassy 
Suspension 
Phase 1 1 1 2 2 2 2 
API mole-
cularly 
dispersed 
mole- 
cularly 
dispersed 
mole- 
cularly 
dispersed 
crys- 
talline 
crys-
talline 
amorphous amorphous 
crystalline 
Carrier crystalline amorphous crystalline 
amorphous
crys- 
talline 
crys-
talline 
crystalline amorphous 
 Key: API, active pharmaceutical ingredient 
 
2.2.1. Preparation methods of solid dispersions 
As mentioned earlier, generally methods can be divided into solvent and 
thermal melting/fusion methods. SDs prepared by a solvent evaporation method 
require a common solvent, where both the drug and carrier are dissolved 
followed by solvent evaporation. Secondary drying step is needed to reduce the 
residual amount of solvent below acceptable limits. Traces of solvent, acting as 
a plasticizer could negatively impact the physiochemical properties of the SDs 
(Janssens and Van den Mooter, 2009). Solvent evaporation method is a better 
option for thermolabile drugs, but potential organic solvent residues and high 
cost of the manufacturing are still a major concern. Moreover, critical process 
parameters such as temperature, evaporation rate, and solvent type affect the 
physical state of the SDs (Janssens and Van den Mooter, 2009; Jermain et al., 
2018; Williams et al., 2016). Spray drying is a common solvent method for 
fabricating pharmaceutical SDs. In spray drying, the drug-polymer solution is 
atomized to tiny droplets, which are immediately dried upon contact with hot 
gas, and the subsequent drug-polymer precipitate in the form of particles is 
collected (Van Den Mooter, 2012).  
In case with thermal methods, SD is formed through heating the drug and 
carrier above their melting point followed by rapid cooling. Afterwards, material 
is pulverized to obtain the powder. Industrial version of thermal method is HME, 
where the powder mixture is supplied through the hopper into the heated barrel 
with screw elements for mixing/kneading and conveyeing the molten mass 
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through the die shaping the final melt into granules, ribbons, or pellets (Janssens 
and Van den Mooter, 2009; Williams et al., 2016). Advantage of thermal 
method is the avoidance of any organic solvents and a drying step. However, 
the chemical stability of drug(s) should be kept in mind, since there is a signi-
ficant risk for chemical decomposition and for the formation of chemical degra-
dation products resulting in an impaired drug-carrier miscibility (Forster et al., 
2001). Most of the commercial amorphous SDs are prepared either by spray-
drying or HME (Table 2). Other non-conventional methods for SDs preparation 
for pharmaceutical applications include supercritical fluid, electrospinning 
(solvent/melt), and more recent a microwave irradiation method (Doreth et al., 
2017; Janssens and Van den Mooter, 2009; Vasconcelos et al., 2007; Brough 
and Williams, 2013).  
 
2.2.1.1 Quench cooling of the melt 
Quench cooling (QC) of a drug-carrier melt followed by pulverization is a 
common technique for manufacturing pharmaceutical SDs (Janssens and Van 
den Mooter, 2009; Vasconcelos et al., 2007). The current trend is to first heat up 
a carrier material, and subsequently suspend the drug inside a molten carrier 
matrix (Vasconcelos et al., 2007). In order to prevent spontaneous recrystalli-
zation, the addition of a stabilizing carrier is of critical importance (Vasconcelos 
et al., 2007). In QC, the cooling rate of a melt should be faster than recrystalli-
zation rate for preventing any molecular mobility and retaining an amorphous 
structure (Brough and Williams, 2013). For example, ice bath and liquid 
nitrogen are applicable for rapid cooling of the system in QC.  
 
2.2.1.2 Melt-electrospinning 
Electrospinning (ES), also called as “electrostatic drawing”, is a nano and 
micro-fabrication method, in which a continuous liquid jet from a polymer 
solution or melt under syringe pump force is electrostatically directed onto a 
grounded collector. Melt-electrospinning (MES) is a thermal modification of 
ES, and MES can be carried out in both horizontal and vertical positions. 
Modified MES constitutes from tuned process environment, where electro-
spinning is carried out under vacuum with higher electrical fields overcoming 
viscosity and elasticity of the polymers. Main limitations is that in vacuum 
radiation cooling can be used only and hence solidication takes longer time, 
posing a risk for fusiong of MSFs (Reneker and Yarin, 2008). Suitable heating 
systems for MES are e.g., thermostated circulating fluids, lasers, radiant heating 
systems, heated air or electrical heating systems (Hutmacher and Dalton, 2011). 
The critical process and material parameters of MES include e.g., melt 
viscosity, process temperature, spinneret diameter, flow rate, voltage, collection 
distance, and a collector type (Brown et al., 2016). These parameters can greatly 
affect the fiber alignment and morphological properties of the final MSFs. The 
flow rate and polymer molecular weight are directly related to fiber diameter 
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and voltage to fiber uniformity (Brown et al., 2011; Brown et al., 2014; Detta et 
al., 2010). According to the literature, the MSFs are smooth, with a small inter-
fiber diameter deviation, and the fiber size typically ranges from 270 nm to 500 
µm (Dalton et al., 2006; Lyons et al., 2004). This also shows a great flexibility 
of the process.  
The carriers intended for QC, MES and HME must be chemically and 
physically stable with sufficient thermoplasticity, and they need to support the 
drug release through solubilizing the released drug or stabilizing the super-
saturated drug solution. Excipient functionality should be maintained throug-
hout the manufacturing process, storage and in vivo. Thermal methods pose a 
significant risk for the degradation of drug and carrier. Therefore, the selection 
of a suitable thermostable carrier material is of crucial importance. Carriers with 
high Tg-s are preferred and functional groups for intermolecular interaction 
(hydrogen bonding) with drug are desirable. Carriers should also provide proper 
miscibility with drug, since drug solubility in the polymer mixture determines 
the upper limit of the drug concentration, showing no phase separation and 
crystallization. If the drug amount exceeds the solubility limit (above 
miscibility), phase separation with following crystallization may occur and 
solubility advantages of SDs will be lost (Marsac et al., 2006; Marsac et al., 
2008b). Hence, the assessment of drug-carrier miscibility is important. Fourier 
transform spectroscopy (FTIR), microscopy and differential scanning calori-
metry (DSC) could be used as fast screening tools. In MES, polymers should 
have also suitable viscosity to pass through a MES spinneret. The molecular 
weight of the carrier has been shown to have the most significant impact on the 
fiber diameter (Brown et al., 2011; Brown et al., 2014). In the present thesis, 
amphiphilic graft copolymer, Soluplus®, SOL (BASF, 2010), was investigated 
as a novel carrier in MES. Originally, SOL was developed as a carrier material 
for HME and hot-melt granulation processes, but due to its unique material 
properties (thermal behavior, solubilizing properties, binding effects, etc.) it has 
also been tested in other pharmaceutical manufacturing processes. Xylitol 
(XYL) is a small-molecular carrier investigated for SD fabrication. It is 
crystalline sugar alcohol used as a matrix of SDs for improving the solubility of 
PWS drugs (Mummaneni and Vasavada, 1990; Sjökvist and Nyström, 1991; 
Singh et al., 2011). Common polymers used for thermal methods and in the 
marketed products are listed in Table 2. 
MES has number of advantages over conventional solution-based ES and SD 
preparation methods: (1) the use of organic solvent(s) can be avoided; (2) the 
yield is exceptionally high (often 100%); (3) the size of fibers is uniform 
(diameter ± 5%), and (4) MES can be readily extended to 3D direct writing 
mode for preparing the scaffolds for tissue engineering (analogue for 3D 
printing). MES fibers made without any organic solvents comply more easily to 
medical device regulations, which also reduces the time for product develop-
ment and marketing authorisation approval (Mitchell, 2015). The major 
limitations of MES are related to the thermal stability of the compounds. 
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Table 2. Currently marketed amorphous solid dispersion (SD) products (modified from Jermain et al., 
2018; Qiu et al., 2017) 
Product API Company BCS 
class 
Carrier Dispersion process 
Afeditab® Nifedipine Elan/Watson 2 Poloxamer or PVP Melt/absorb on carrier 
Certican (non-US) Everolimus Novartis 3 HPMC Melt or spray drying 
Cesamet® Nabilone Valeant 
Pharmaceuticals 
2 or 4 PVP Melt extrusion 
Fenoglide® Fenofibrate LifeCycle Pharma 2 PEG Spray melt 
Gris-PEG® Griseofulvin Novartis/Penidol 2 PEG Melt extrusion 
Ibuprofen® Ibuprofen Soliqs 2 various Melt extrusion 
Incivek® (US) Telaprevir Vertex 
Pharmaceuticals 
2 or 4 HPMCAS Spray drying 
Incivo® (Europe) Telaprevir Janssen 
Pharmaceuticals 
2 or 4 HPMCAS Spray drying 
Intelence® Etravirine Janssen 
Pharmaceuticals 
4 HPMC Spray drying 
Isoptin SRE-240 Verapamil Abbvie Inc 2 HPC/HPMC Melt extrusion 
Kalydeco® Ivacaftor Vertex 2 or 4 HPMCAS Spray drying 
Kaletra® Lopinavir 
ritonavir 
AbbVie 2 and 4 PVP VA Melt extrusion 
LCP-Tacro® Tacrolimus LifeCycle 
Pharma/Veloxis 
2 HPMC Melt granulation 
Nimotop® Nimodipine Bayer 2 PEG Spray drying/fluid bed 
Norvir® Ritonavir AbbVie 4 PVP VA Melt extrusion 
Noxafil® Posaconazole Merck 2 HPMCAS Melt extrusion 
Onmel® Intraconazole GlaxoSmithKline/
Stiefel 
2 PVP VA Melt extrusion 
Orkambi® Lumacaftor/ 
Ivacaftor 
Vertex 2 and 4 PVP/HPMC CAS Spray drying 
Prograf® Tacrolimus Astellas Pharma 
Inc 
2 HPMC Spray drying/fluid bed 
Sporonox® Intraconazole Janssen 
Pharmaceuticals 
2 HPMC Spray layering (fluid 
granulation) 
Venclexta™ Venetoclax Abbvie 4 PVP VA Melt extrusion 
Zelboraf® Vemurafenib Roche 4 HPMCAS Antisolvent 
precipitation 
Zortress® (US) Everolimus Novartis 
Pharmaceuticals 
3 HPMC Melt or spray drying 
Zepatier® Elbasvir/ 
Grazoprevir 
Merck 4 and 2 PVP VA/HPMC Spray drying 
Mavyret™ Glecaprevir/ 
Pibrentasvir 
AbbVie 4 PVP VA/HPMC Melt extrusion 
Key: API, active pharmaceutical ingredient; BCS, Biopharmaceutics Classification System; PVP, 
polyvinylpyrrolidone; HPMC, hydroxypropylmethylcellulose; PEG, polyethylene glycol; HPMCAS, 
hydroxypropylmethylcellulose acetate succinate; PVP VA, polyvinylpyrrolidone vinyl acetate 
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MES is a novel technique which is intensively studied in biomedical and 
pharmaceutical fields. Today, the main application areas of MES include tissue 
engineering constructs and scaffolds. Several studies with osteoprogenitors, 
osteoblasts and fibroblasts showed that MSF polycaprolactone (PCL) scaffolds 
can support the cell growth and extracellular matrix formation (Henkel and 
Hutmacher, 2013; Hutmacher and Dalton, 2011; Thibaudeau et al., 2014). There 
are number of successful animal models, where PCL based scaffolds were used 
for bone bridging and regeneration (Henkel and Hutmacher, 2013). The 
flexibility of MES allows to adjust the mechanical properties of fibers, pore 
size, surface morphology and fibers deposition. The application of MES in the 
pharmaceutical field is in its infancy. To date, only few studies have been 
published on the application of MES as a method for improving the solubility 
and dissolution rate of PWS drugs (Balogh et al., 2014; Lian and Meng, 2017; 
Nagy et al., 2013). 
 
 
2.2.2. Characterization of solid dispersions 
Many characterization methods used for the solid state analysis can be utilized 
for analyzing the SDs. The physicochemical properties and stability of SDs 
immediately after preparation and during storage are generally investigated.  
X-ray powder diffraction (XRPD) is a golden tool for polymorphic screenings 
(sharp reflections) and amorphicity detection („halo“) of drugs and excipients. 
Freshly prepared amorphous SDs should not have any crystalline reflections 
and show only an amorphous halo on their diffractograms. When two-phase 
(crystalline-amorphous) systems are investigated, elevated baseline with 
reduced and broaden crystalline reflections are detected. However, XRPD alone 
might not be sensitive enough to differentiate between discrete amorphous-
amorphous phases, and consequently, other analytical techniques are needed. 
Vibrational spectroscopy methods (infrared (IR), near-infrared (NIR), Raman) 
can be used for the solid-state characterization and quantification (Aaltonen et 
al., 2003). Vibrational spectroscopy methods are fast, non-destructive and 
precise providing chemical and physical data and NIR and Raman spectroscopy 
can be easily coupled with devices for in-line or spatially resolved analysis 
(flow through cells, microscopes, array detectors) (Fraser-Miller et al., 2016). 
Thermal methods such as differential scanning calorimetry (DSC), thermo-
gravimetric analysis (TGA), hot-stage microscopy (HSM), are widely used to 
study the miscibility of the systems, recrystallization and moisture content. In 
case of amorphous solids, there is no melting endotherm of a drug observed. 
Regarding with miscibility, only one Tg value for miscible systems and two Tg 
values for immiscible systems (less stable formulations) will be detected (Qian 
et al., 2010). With the TGA, a weight loss of MSF can be observed, thus 
indicating the dehydration and potential thermal decomposition of the system.  
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2.2.3. Physical stability of solid dispersions 
In order to sustain pharmaceutical quality and functionality, the drug-loaded 
SDs must be chemically and physically stable. The SDs must be formulated and 
stored in a way which enables to reduce the risk of product degradation or 
polymorphic changes. Environmental factors affecting the formulation stability 
are humidity, temperature, light, and oxygen. All these factors may change the 
mechanical properties and disintegration time of dosage form, induce poly-
morphic transformation of API to less water-soluble form, accelerate chemical 
degradation and/or impair the physical appearance of the final product. In 
addition, SD fabrication methods have their own limitations and challenges. For 
example, drug and excipients are subjected to a high temperature in HME or 
MES, which can result in the decomposition of drug/excipient. With solvent 
evaporation methods, the traces of organic solvent residuals can induce the 
polymorphic transformations resulting in variable solubility, dissolution rate 
and bioavailability of the drug. The use of organic solvent also rises the toxicity 
issues and safety hazard during the handling process. Hence if solid phase is 
sensitive to heat, solvent evaporation methods must be chosen and vice versa. 
In order to stabilize amorphous form, the inclusion of a proper excipient in 
the system is needed. However, unique physical and chemical properties of 
carrier(s) can significantly limit the formulation stability. It has been shown that 
some polymers (e.g., polyethylene glycol, PEG) are prone to recrystallization on 
the course of storage, thus resulting in the reduced dissolution rate of the final 
product (Bley et al., 2010). Moreover, hygroscopicity of the polymers is 
disrupting the interactions between the drug and carrier, lowering the solubility 
or miscibility of the drug in the carrier, increasing the molecular mobility and 
favoring the phase separation leading to crystallization (Marsac et al., 2008b). 
As an example, the storage of hydrophobic drugs ((nifedipin, griseofulvin, 
polyvinyl pyrrolidone (PVP)) SDs at high relative humidity led to an 
amorphous-amorphous phase separation, and subsequently the crystallization of 
the drugs (Rumondor et al., 2009). With amorphous SDs, both absorption and 
adsorption phenomena can occur, where water is attracted into internal site or 
on the surface of the system, respectively. Therefore, amorphous SDs show 
higher sorption values (absorption plus adsorption) compared to the corres-
ponding physical mixtures (PM) (Crowley and Zografi, 2002). As mentioned 
earlier, SOL has proved to have stabilizing (recrystallization retardation/ 
inhibition) and solubility enhancing properties with pharmaceutical SDs, thus 
resulting in improved wettability and dissolution of PWS (Linn et al., 2012; 
Shamma and Basha, 2013). Yamashita et al. (2003) investigated the effect of 
polymeric precipitation inhibitors ((PEG6000, hydroxypropylmethyl cellulose 
(HPMC), PVP)) as a means for improving the absorption of PWS. Nevertheless, 
excipients with high Tg, will significantly reduce the molecular mobility and 
stabilize the supersaturated drug.  
A complete miscibility of the components is desired to gain a stable formu-
lation. For estimating the miscibility, a simple DSC scan be used, where 
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miscibility between the drug and polymer during heating-cooling-heating cycle 
is assessed (Sarode et al., 2013). As mentioned earlier, a single Tg value con-
firmes the miscibility, whereas two Tg values suggest partial miscibility. 
However, DSC does not take into account the heat induced co-fusion or recrys-
tallization. Another interesting classification system for SDs was introduced by 
Baird and co-workers (2010) which relies on the glass forming ability (GFA) 
and glass stability (GS) assesment. In order to form a glassy SD, mixture must 
be QC below Tg to prevent the nuclei formation (GFA) and resistance of such 
material to crystallization upon cooling is known as GS. Intial DSC stability 
assessment based on fast screening was performed with total 51 APIs. 
According to Baird et al. (2010), the compounds which recrystallized upon 
cooling are weak glass formers (Class I) and those which crystallized upon 
reheating are strong glass formers (Class II). The strongest glass formers are 
regarded as those which did not show any recrystallization (Class III). The 
compounds belonging to Class I (e.g., carbamazepine, benzocaine, halo-
peridole) or Class II (e.g., acetaminophen, celecoxib, nifedipine) are categorized 
as high risk compounds in formulating stable amorphous SD. Whereas the Class 
III (e.g., ibuprofen, indomethacin, ketoprofen) compounds are considered as 
excellent candidates for formulating stable amorphous SDs. It was noted that 
high molecular weight and complex structure are the key properties for strong 
glass formers (Baird et al., 2010).  
 
 
2.2.4. Pharmaceutical application of solid dispersion 
Examples of currently marketed amorphous SDs are depicted in Table 2. As 
seen in Table 2, mostly they were prepared either by melt extrusion or spray 
drying. As an example, Sporanox® molecular disperison of PWS itraconazole 
within the HPMC and attached to sugar beads. Compared to the crystalline 
drug, the amorphous SDs showed significant improvement in bioavailability 
(Eerdenbrugh et al., 2009). The number of marketed amorphous SDs is 
relatively low, however positive increasing trend has been seen for recent years. 
The reason for small number of marketed products is the instability of 
amorphous system, which tend to recrystallize during manufacture, storage, or 
drug release, and which result in loss of favorable dissolution profile. Also, 
limited number of suitable pharmaceutical excipients with reasonable solubility 
in organic solvents for solvent based techniques and appropriate viscosity and 
thermal stability of thermal methods is a concern. 
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3. SUMMARY OF THE LITERATURE 
As it can be concluded, poorly water-soluble drugs remain a big challenge for 
pharmaceutical industry, hindering bringing to market efficient therapeutical 
agents. The number of such drugs are expected to grow in following years. 
Limited solubility and/or dissolution rate coming from physicochemical pro-
perties of chemical entity, raises the need for novel methods or optimizing 
existing ones. Also, limited number of suitable pharmaceutical excipients is 
slowing the development process. Solid dispersion preparation technique has 
shown its potential in numerous marketed products. However, miscibility/ 
stability of the formulation is still a significant challenge. The application of 
modified thermal methods coupled with potentially new pharmaceutical 
excipients could be a new solution for an old problem. 
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4. AIMS OF THE STUDY 
The aim of the present thesis was to investigate and gain understanding of the 
effects of two thermal pharmaceutical solid dispersions fabrication methods on 
the physicochemical properties, physical stability and dissolution behavior of a 
poorly water-soluble drug indomethacin.  
 
The specific objectives were: 
‒ to investigate the solid-state stabilization properties of the solid dispersions 
with two matrix formers (Soluplus®/xylitol)  
‒ to investigate the particle and bulk powder properties, wetting and 
dissolution of the quech cooled molten two-phase solid dispersions of a 
poorly water-soluble indomethacin and selected two matrix formers  
‒ to elucidate the impact of polymeric and crystalline carrier properties on the 
formulation and performance of SDs with a major emphasis on the dis-
solution studies 
‒ to develop novel drug-loaded melt-electrospun fibers using MES for 
improving the dissolution rate of a poorly water-soluble drug 
‒ to gain understanding of the physical solid-state changes, drug-carrier polymer 
interactions, and dissolution rate associated with melt-electrospun fibers 
 
 
 
  
26 
5. EXPERIMENTAL 
Complete description of materials and methods the reader should refer to 
original publications (I–III). 
 
 
5.1. Materials  
5.1.1. Indomethacin 
Indomethacin (IND) is a widely-used non-steroidal anti-inflammatory drug, and 
is a commonly used model drug in the development of amorphous systems for 
PWS drugs (Hart and Boardman, 1963; Ewing et al., 2014; Dimensional et al., 
2015). IND has two crystalline polymorphs (α and γ forms) and an amorphous 
form (Atef et al., 2012; Savolainen et al., 2007; Clare J Strachan et al., 2007). 
Recently, Surwase et al. (2013) discovered and characterized several new 
polymorphs (ɛ, ζ, η) for IND, which were prepared under different crystalli-
zation conditions (Surwase et al., 2013). In the present thesis, IND (γ-IND) 
(NLT 97.5%, Acros Organics, England and Hawkins, USA) was used as a PWS 
model drug. The preparation of α-polymorph and amorphous forms of a model 
drug IND can be found in the original publications (I–III).  
 
 
5.1.2. Soluplus® 
Soluplus® (SOL) is a new amphiphilic graft copolymer for pharmaceutical 
applications (BASF, 2010). Chemically SOL is a graft copolymer consisting of 
polyvinyl caprolactam-polyvinylacetate-polyethylene. SOL has been regarded 
as a bifunctional polymer having matrix forming and solubilizing properties for 
PWS drugs (Shamma and Basha, 2013). Originally, SOL was developed as a 
carrier material for HME and hot-melt granulation processes (BASF, 2010). In 
the present study, SOL was received as a gift from BASF SE (Pharma 
Ingredients & Services, Germany) and it was used as a solubilizing polymeric 
matrix former in both the QC molten and MES SDs (I–III).  
 
 
5.1.3. Xylitol 
Xylitol (XYL) is a sugar alcohol, which is widely used as a non-cariogenic 
sugar substitute in confectionary and dental hygienic products (Salli et al., 
2016). To date, it has gained attention in the pharmaceutical use as a small-
molecular matrix of SDs for improving the solubility of PWS drugs 
(Mummaneni and Vasavada, 1990; Singh et al., 2011; Sjökvist and Nyström, 
1991). In the present thesis, XYL (Ph. Eur.) was obtained from Yliopiston 
Apteekki (Helsinki, Finland), and it was used as a small-molecule freely soluble 
SD matrix former (I, II).  
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5.2. Methods for fabricating physical mixtures and  
solid dispersions 
5.2.1. Preparation of physical mixtures (I–II) 
The physical mixtures (PMs) of a drug and carrier were prepared by mixing the 
components with a pestle in a mortar and using a geometric dilution. PMs were 
prepared with SOL/XYL and both IND polymorphs (γ-IND and α-IND). 
Samples were sieved using a mesh of 450 μm, and the fraction passing through 
was collected for further use (I). The drug:carrier weight ratios used in the PMs 
were 1:3, 1:6 and 1:9 (w/w) (drug:polymer) (I). In the subsequent studies, pure 
materials were sieved (150 μm) prior to use and characterization (II, III).  
 
 
5.2.2. Preparation of solid dispersions by melt quench cooling (I–II) 
For preparing the solid dispersions (SDs) by melt quench cooling (QC), the 
traditional QC method, explained in the Literature review under paragraph 
2.2.1. Preparation methods of solid dispersions (SDs), was modified in the 
present study. In the present PhD thesis, two-phase drug-carrier systems were 
prepared with an unorthodoxic and modified QC method, where the drug (not 
carrier) was molten first followed by the addition of the carrier (I). QC co-
melted SD mixtures were prepared by melting the γ-IND in a stainless steel dish 
at approximately 175 °C and then adding SOL/XYL. Therefore, the molten 
mass was solidified by pouring liquid nitrogen onto the stainless steel dish. The 
molten mass was then gently ground in a mortar. All samples were sieved using 
the same fraction as PMs. The SDs with the weight ratios 1:3, 1:6, 1:9 (w/w) 
(drug:polymer) were investigated (I). In the subsequent studies, SDs at the 
weight ratio 1:3 (w/w) (drug:polymer) were used (II–III).  
 
 
5.2.3. Melt-electrospinning (III) 
Prior to use, the drug and carrier polymer were manually sieved through a  
150-μm size sieve. The PMs were prepared as described in the original publi-
cation (I). The batch size of each PM was 6.0 g. The PM1 and PM3 consisted of 
crystalline γ-IND and SOL (1:3). The PM2 consisted of amorphous IND 
prepared by QC of a melt and subsequently mixed with SOL at a drug-polymer 
weight ratio of 1:3. The PMs 1 and 2 were used as reference samples and PM3 
was used as a binary pretreated mixture for the MES experiments (III). 
Pretreatment was performed by storing the PM of γ-IND and SOL (1:3) at high 
relative humidity (approx. 90% RH) for 24 h prior MES. 
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5.3. Characterization of physical mixtures and  
solid dispersions 
5.3.1. Scanning electron microscopy (I–III) 
Scanning electron microscope (SEM) (Zeiss EVO MA 15, Germany) was 
exploited for imaging the particle/fiber size, shape, surface porosity and 
morphology of the samples. The samples were attached on a carbon tape, and 
sputter coated with platinum (3–5 nm) in an argon atmosphere. The measure-
ments were carried out under low vacuum. Martin’s diameter of 50 randomly 
selected particles was determined in vertical direction from SEM images and 
particle size was measured by Image J (NIH, USA). 
 
 
5.3.2. X-ray powder diffraction (I–III) 
The X-ray powder diffraction (XRPD) patterns of rotating samples were 
collected with a Bruker D8 Advance diffractometer (Bruker Corporation, 
Germany) using Cu radiation λ=1.5418 Å and operated at 40 kV and 40 mA. 
For data gathering, theta–theta geometry in the range of 5°–35° 2θ (with the 
step size of 0.0195° 2θ) and a LynxEye positive sensitive detector, were 
applied. Variable-temperature XRPD (VT-XRPD) was used for tracking the 
heat induced solid-state transitions and understanding the miscibility of the 
systems and revealing the presence of multi-phase system. Data were collected 
from 8 to 22.5° 2θ, with a step size of 0.0195° 2θ. The heating process started 
from RT at a rate of 0.5 °C/min and the first scan was taken at 30 °C and other 
scans were measured at intervals of 10 °C up to 150 °C for IND:SOL systems 
and after every 5 °C until 160 °C for all systems. The heated samples were then 
cooled down to 30 °C and remeasured. 
 
 
5.3.3. Fourier-transform infrared spectroscopy (I–III) 
Fourier transform infrared spectroscopy (FT-IR) spectra of samples were 
collected with IR Prestige-21 Spectrophotometer (Schimadzu Corp., Kyoto, 
Japan) and Specac Golden Gate Single attenuated total reflection (ATR) crystal 
(Specac Ltd., Orpington, United Kingdom). Operating range was 4000–600 cm–1.  
 
 
5.3.4. Near-infrared spectroscopy (III) 
Near-infrared spectroscopy (NIR) spectra (1200–2200 nm) were measured with 
AvaSpec-NIR256-2.2 (Avantes, The Netherlands), equipped with 256 pixel in 
GaAs detector and tungsten halogen lamp as a light source (AvaLight-HAL). 
The final spectrum was the mean of total four scans, and each sample was 
measured in pentaplicate.  
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5.3.5. Nuclear magnetic resonance spectroscopy (III) 
Nuclear magnetic resonance spectroscopy (NMR) with 1H and 13C FT-NMR-
spectra in CDCl3 (Eur-isotop 99.80% containing 0.03% TMS) solution together 
with 13C CP-MAS spectra in solid state were recorded using Bruker Avance III 
500 MHz spectrometer (Bruker, UK Limited, United Kingdom). Solution 
spectra were recorded in 5-mm glass tubes and solid state spectra in 4-mm 
rotors. All spectra were recorded at 23 °C. In order to calculate the approximate 
domain size, equation 2 (Brettmann et al., 2012) was used: 
 
                          ܮ = (6ܦ ௜ܶ)ଵ/ଶ (Eq. 2) 
 
where L is the magnetization diffusion length, D is the spin diffusion coefficient 
and Ti is the relaxation time. In this study, approximate values of D,  
8.0×10–16 m2/s for rigid systems and 0.5×10–16 m2/s for mobile systems were 
used reported earlier by Spiegel et al. (1994). Because the rigidity/flexibility of 
the system is not precisely known the domain sizes were presented as a range 
and the result gives upper limits for the domain size.  
 
 
5.3.6. Differential scanning calorimetry (I–III) 
Differential scanning calorimetry (DSC) 4000 (Perkin Elmer Ltd., Shelton, CT, 
USA) was used for the thermal analysis of samples in an aluminum pans with 
pinholes in a lid and under a dry nitrogen flow. The key parameters used in the 
DSC experiments were as follows: sample size (2–8 mg), heating rate 
(10 °C/min), and operating temperature range (20–200 °C). The DSC system 
was calibrated with indium.  
Hot-stage microscopy (HSM) was performed with a Mettler Toledo F82 
(Switzerland) and visualized with a polarized light microscope (Leica DM/LM, 
Germany) under 5× magnification (HSM-PLM). The temperature range and 
heating rate were 30–200 °C and 20 °C/min, respectively.  
 
 
5.3.7. Thermogravimetric analysis (II) 
Moisture content and thermal stability was assed with thermogravimetric analysis 
(TGA) performed with a NETZSCH STA 449 F3 Jupiter® (NETZSCH- 
Gerätebau GmbH, Germany) simultaneous thermal analyzer. Air was used as a 
purge gas at the flow rate of 60 ml/min. Samples (25–35 mg) were placed in 
corundum sample holders. The sample was heated from 20 °C to 350 °C at the 
rate of 10 °C/min and held isothermally at 350 °C for 10 min. Data were pro-
cessed with NETZSCH Proteus® Software for Thermal Analysis. Thermal chan-
ges up to 150 °C were taken as a dehydration process. 
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5.3.8. High-performance liquid chromatography (III) 
The content and chemical stability of IND in MSFs (three different batches, 
n=8) was assayed by high-performance liquid chromatography (HPLC) (254 nm) 
using slightly modified European Pharmacopeia (Ph. Eur. 9.0) method. HPLC 
system (Shimadzu Prominence LC20 with PDA detector SPD-M20A) 
controlled by software LC solution was used. The standard of IND (~0.15 mg/ml) 
was dissolved in acetonitrile:water solution (1:1). A Phenomenex Luna2 C18 
column was used with the flow rate of 1.0 ml/min and injection volume 10 µl at 
the temperature of 50 °C. The following mobile phases were used: (A) 10 g/l 
solution of 30% (m/V) acetic acid in water, (B) 10 g/l solution of 30% (m/V) 
acetic acid in acetonitrile. HPLC was also used to confirm the results of drug 
release from MSFs obtained by UV-Vis spectrophotometer (Specord® 200 
Plus, Analytik Jena AG, Germany). 
 
 
5.3.9. Karl-Fischer titration (II) 
Karl-Fischer (KF) titration (Mettler Toledo V30 Volumetric KF Titrator, Mettler-
Toledo GmbH, Schwerzenbach, Switzerland) was used for determining the total 
water content of materials. The KF titrations (n = 2–3) were carried out at 21 °C 
temperature / 22% relative humidity (RH).  
 
 
5.3.10. Moisture sorption and contact angle measurements (II) 
The moisture sorption of the drug, carrier materials, PMs and SDs was investi-
gated by storing the pre-weighed samples in open petri dishes. The petri dishes 
were kept at a constant temperature (25 °C) and RH 95% for 7 days. All 
samples were kept at 30 °C for 24 h before the first weighing. The moisture 
sorption was calculated from the weight gain using the following equation 
(Eq. 3) (Maddineni et al., 2015): 
 
                                      ܩ = ሾ(ݓ݂ − ݓ݅)/ܵሿ ݔ 100  (Eq. 3) 
 
where S is the initial mass of the sample, wi is the total original mass of a petri 
dish and the sample, and wf is the total end mass of a petri dish and the sample. 
Total three parallel determinations were performed. 
Contact angle measurements (CAM200, ver. 4.1, KSV Instruments, Finland) 
were performed with the flat-faced compacts (m = 300 mg) prepared using a 
table top hydraulic press with a 13-mm die. Each compact was pressed using 
100 MPa of pressure for 30 s. A purified water drop (MilliQ, EMD Millipore 
Corporation, Billerica, MA, USA) was used as the testing liquid. Images were 
taken within 40 ms after the liquid drop touched the surface of the compact, and 
both angles were recorded.  
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5.3.11. Powder flow test (II) 
The powder flow was determined using a novel in-house flow testing device 
(Fig. 1; II). The flow testing device has a sample cuvette mounted on a stepper 
motor, which was controlled with a custom-made software. The cuvette 
consisted of two vertically positioned chambers separated by a 3 mm orifice. 
The powder was placed in the left chamber, and the cuvette was subjected to a 
specific acceleration profile, consisting of a slow acceleration and rapid 
deceleration when moving to the right and a rapid acceleration and slow 
deceleration when moving to the left. As a result of the acceleration profile and 
based on Newtonian mechanics, the powder is able to gradually move to the 
opposite chamber through the orifice. When the powder was completely trans-
ferred to the opposite chamber, the measurement was terminated. The result was 
expressed as the amount of powder transferred per movement (mg/movement). 
The acceleration profile was programmed using MATLAB (The MathWorks, 
Inc., Natick, MA, USA). The testing method was validated with known 
excipients and against comparable powder flow measurements found in the 
literature (Seppälä et al., 2010). 
 
 
5.3.12. Dissolution test (II–III) 
The dissolution tests were carried out using an USP paddle method (Distek 
Dissolution system 2100B, Distek, Inc., NJ, U.S.A). A table-top UV–VIS 
spectrophotometer (Specord 200 plus, AnalyticJena, Germany) was used at the 
analytical wavelength of 370 nm for the analysis of the PM and SD samples 
(n = 3). Prior to experiments, it was verified that neither SOL nor XYL showed 
any absorption at this specific wavelength. The two buffer solutions (Ph. Eur. 
9.0), pH 1.2 and pH 6.8, were used as dissolution media at 37.0 ± 0.5 °C. The 
total volume of the medium in each dissolution vessel was 500 ml. The rotation 
speed of the paddles was set at 100 rpm. At regular time intervals (10, 20, 30, 
60, 360, and 1440 min), the samples of 5 ml were manually collected with a 
syringe and replaced accordingly with the pure buffer solution in a dissolution 
vessel. The samples were filtered using a 25-mm syringe filter (VWR, USA) 
and through cellulose filters with a pore size of 45 µm. The first 2 ml of the 
filtrated solution was not included in the quantitative analysis with a UV-VIS 
spectrophotometer. 
 
 
5.4. Storage stability studies (I) 
For assessing the physical stability of prepared multi-phase SD systems and 
revealing possible phase transitions and/or polymorphic changes, the QC molten 
SDs were stored in open glass petri dishes at 0% RH, 50% RH and 75% RH at 
RT (23 ± 2 °C) for up to 2 months. The samples of the aged SDs stored under 
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50% and 75% RH were taken periodically every 24 h during the first week, and 
subsequently after 10 days, 14 days, 21 days and 27 days. The samples stored at 
0% RH were monitored for up to 2 months. In addition, the SD of IND with 
XYL (a drug-carrier weight ratio 1:3) was taken for the short accelerated 
stability testing and stored only at 50% RH/RT up to 4 days. 
 
 
5.5. Data analysis 
ImageJ (version 1.50b) software was used to measure the particle size (Martin's 
diameter) and particle size variation. OriginPro (versions 9.1 and 8.5) software 
was used for plotting figures. Particle size normality distribution was analyzed 
with a Shapiro-Wilk test. ChemBioDraw Ultra (version 13.0) drawing program 
was used for structure generation. The statistical analysis (p ˂ 0.05) of contact 
angle results was performed with a ANOVA one-way test and Tukey test. 
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6. RESULTS AND GENERAL DISCUSSION  
Summary of present thesis has been depicted in Fig. 2. Modified quench 
cooling (QC) of the melt and melt-electrospinning carried out with different 
carriers resulted in one-phase/multi-phase system solid dispersions (SD). As a 
result, improved dissolution rate with SD was achieved.  
 
Fig. 2. Schematic illustration of solid dispersion preparations used in this thesis and the 
key results. Key: MSF – melt-spun fiber, QC – quench cooled, SOL – Soluplus®, 
XYL – xylitol, IND – indomethacin.  
 
 
6.1. Classification of solid dispersions (I–III) 
The formulation of pharmaceutical SDs does not always result in molecularly 
dispersed one-phase systems and different multi-phase SDs have been classified 
according to the solid state of the components and their stability (Thommes et 
al. 2012). In the present doctoral study, it was of interest to understand the 
relative stability of two-phase systems compared to the corresponding PMs and 
one-phase amorphous SDs systems. Furthermore, the crystallinity of the carrier 
material may effect the formulation of SDs and its properties. The use of 
crystalline and semicrystalline carriers, such as freely water-soluble sugars, 
Solid dispersions
Melt-electrospinning
XylitolSoluplus®
Quench cooling (modified)
Soluplus®
glassy suspension amorphous precipitate amorphous solid dispersions
two-phase systems one-phase systems
Dissolution rate↑
500x
500x
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promotes ingress of hydration media into the SD. With amorphous polymer 
carriers, drug crystallization is prevented through intermolecular interactions 
with the polymer. However, large bulk volumes of polymer need to be used to 
reduce the mobility and increase local viscosity. The hygroscopicity of the 
polymer can also destabilize the amorphous system (Löbmann et al., 2013; 
Williams et al., 2013). Compared to amorphous carrier, crystalline carrier can 
act as a nucleation surface for the crystallization of drug followed by nucleation 
and crystal growth (Duong et al., 2015). Based on the phase separation and 
physical solid-state form of drug (IND) and carriers (SOL, XYL), the QC 
molten SDs were classified into different categories as shown in Table 1 (I). 
The fresh QC molten amorphous SDs of IND with SOL were two-phase glassy 
suspensions in which the drug is in amorphous form within the amorphous 
polymer matrix. After a short-term aging, the amorphous SDs may still contain 
the drug (IND) in an amorphous form or partially crystalline form depending on 
the storage conditions. The fresh QC molten SDs systems of IND with XYL 
were characterized as two-phase amorphous precipitation systems in which the 
drug is in an amorphous form in the crystalline sugar alcohol matrix. However, 
a short-term aging of the present SDs systems results in the formation of a two-
phase solid crystal suspension in which IND is in a crystalline form together 
with crystalline XYL. The fibrous SD (MSFs) prepared by MES with SOL can 
be apparently regarded as an amorphous glassy solution or amorphous SD with 
a superior dissolution rate. 
 
 
6.2. Quench-cooled molten solid dispersions  
of indomethacin and Soluplus® (I, II) 
6.2.1. Physical solid state drug-carrier interactions (I) 
Understanding of the thermal phase behavior and polymer-drug interactions of 
the two-phase binary system is of key importance for the selection of the most 
suitable carrier. Thermal stability of the fresh QC molten SDs at the weight ratio 
of 1:3 (drug:polymer) as well as drug-polymer miscibility was studied using 
DSC, MT-DSC, HSM and VT-XRPD. As a reference, the thermal behavior of 
all pure materials and corresponding PMs were studied. In line with the XRPD 
results, the absence of a melting endotherm on the DSC thermograms of freshly 
prepared QC SDs with IND:SOL provided evidence of the formation/presence 
of amorphous systems (Table 1, I). Upon heating no heat-induced recrystalli-
zation was observed in the DSC thermograms. Due to the broad endothermic 
artifact from 30–100 °C in the conventional DSC, the Tg-s of amorphous IND 
and SOL were indistinguishable and it was impossible to understand the 
presence or absence of multiple phases of this drug-carrier system. In order to 
investigate this further and unambiguously identify the Tg-s as well as classify 
the SDs according to their structure (one or multi-phase systems), MT-DSC 
experiments were conducted. The MT-DSC with QC SDs of IND:SOL (1:3) 
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system showed a two-phase SDs system, where on a reversing thermogram two 
Tg-s were clearly observed: the first one at 40.3 °C for amorphous IND and the 
second one at approximately 88 °C for SOL (Fig. 4, I). Clear shift in Tg-s of 
IND-SOL SDs compared to the pure materials confirmed some level of drug 
polymer miscibility important for the stability of amorphous systems. 
HSM-PLM was also used to visualize the DSC/MT-DSC results and get 
more insight into the phenomena occurring at the interfaces within SD and PM 
mixtures (Fig. 3). The QC molten IND:SOL mixtures were heterogeneous and 
consisted of darker particles and more yellowish particles, hence no birefrin-
gence was observed confirming the presence of two-phase amorphous SDs 
system (Fig. 3). Upon heating no crystals were observed in these systems, only 
the drug dissolution into a polymer melt was detected. Similar phenomenon has 
been described by Fini and co-workers (2008) with ibuprofen and diclofenac, 
when they investigated the interactions between these two drugs with different 
types of PVP in PMs and SDs.  
 
 
 
Fig. 3. Photomicrographs of indomethacin (IND) fresh solid dispersion systems (SDs) 
and their respective physical mixtures (PMs) with γ-IND. A. SDs with Soluplus® 
(SOL) IND:SOL in weight ratio of 1:3 (drug:polymer); B. PMs with Soluplus (SOL)  
γ-IND:SOL in weight ratio of 1:3 (drug:polymer). Scale bar of 100 µm. 
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Fig. 4. Attenuated total reflection Fourier Transform Infrared (ATR-FTIR) spectra of 
indomethacin (IND) fresh solid dispersion systems (SDs) with γ-IND. SDs with 
Soluplus® (SOL) IND:SOL in different weight ratios (1:3, 1:6, 1:9 (drug:polymer). The 
(*) and (#) marks denote the reflections unique to γ-IND and α-IND, respectively. 
 
 
Interestingly, VT-XRPD results showed that the amorphous SDs of IND and 
SOL started to recrystallize as α-IND at 70 °C (Fig. 5A, I). The most pro-
nounced reflections of α-IND were detected at 100 °C (denoted with # on Fig. 
5B, I). This confirmed that SOL is not able to entirely prevent the heat-induced 
phase separation and recrystallization of α-IND. Differences between VT-XRPD 
and other thermal techniques (DSC, MT-DSC, HSM-PLM) can be explained 
with much longer measurement time in the VT-XRPD experiments, which may 
induce more pronounced changes in the sample upon heating (Mirza et al., 
2006). 
Since thermal analysis revealed that IND-SOL SD has some mixing between 
the components, the ATR-FTIR spectroscopy was used to examine further the 
possible molecular-level interactions between the drug and carrier in SD 
systems. The pure material spectra matched with the reported spectra in the 
literature (Bahl and Bogner, 2006; Lan et al., 2010; Shamma and Basha, 2013; 
Clare J. Strachan et al., 2007). The ATR-FTIR spectra of IND-SOL amorphous 
SDs at all drug:polymer weight ratios showed strong absorption peaks at 
1630 cm–1 and 1732 cm–1 (Fig. 4) which belong to SOL molecular vibrations 
(carbonyl groups of block sequences – polyvinylacetate O–C=O–CH and 
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caprolactam C=O–N vibrations, respectively). Since the pure amorphous IND 
also showed shoulder band at 1734 cm–1 and strong vibrations at 1689 cm–1 and 
1679 cm–1, the spectral overlap with strong SOL vibrations covered several 
amorphous IND peaks. However, as evidenced by the MT-DSC results (shift in 
Tg of IND-SOL SDs compared to pure materials), some hydrogen-bond 
formation at the molecular level may have occurred between SOL and IND 
molecules during SD preparation (peak observed at 1680 cm–1). Zhang et al. 
(2013) described similar interaction with the SDs composed of itraconazole and 
SOL. 
 
 
6.2.2. Particle size, shape and surface morphology (I, II) 
Comparison of the SEM results of pure materials with those obtained with the 
QC molten SDs can help to indicate the influence of the method of preparation 
and carrier on the particle size, shape and surface morphology. All mixtures 
(1:3, 1:6, 1:9) were initially prepared, but only 1:3 was tested further. Fig. 5 
illustrates the SEM images of the particles representing the solid-state forms of 
IND (A-C) and the two carrier materials studied (D, E). 
The γ-form of IND displayed pointed and plate-like particles (Fig. 5, A), 
whereas the particles of α-IND were clearly needle-like in shape (Fig. 5, B). 
SOL had the largest particles ranging from 100 to 200 μm in diameter, and  
γ-IND the smallest ones with a size range below 50 μm. The PMs showed 
clearly distinguishable γ-IND particles and larger carrier particles and in SDs 
fused drug particles on polymer surface can be detected (Fig. 6). 
 
 
Fig. 5. SEM micrographs of pure materials. Key: A – γ-IND; B – α-IND; C – 
amorphous IND; D – SOL; E – XYL. Key: IND = indomethacin; SOL = Soluplus®; 
XYL = xylitol. Magnification: ×100 and ×500. 
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Fig. 6. SEM micrographs of physical mixtures (PMs) and quench cooled (QC) molten 
solid dispersions (SDs). Key: A1 – PMs of γ-IND and SOL (1:3); A2 – SDs of IND and 
SOL (1:3). Key: IND = indomethacin; SOL = Soluplus®. Magnification: ×500. Drug 
particles are indicated by arrows. 
 
 
6.2.3. Powder flow (II) 
Characterization of powder flow is an important aspect in formulating efficient 
pharmaceutical product. Hence, the powder flow of pure materials, PMs and 
SDs were evaluated using an in-house automated cuvette rheometer designed 
for testing in a small scale (Fig. 1, II). Fig. 7 shows the dependence of the number 
of cuvette movements and the sample mass in the chambers, thus quantifying 
the powder flow rate (mg/movement) of the sample. As expected, the powder 
flow of pure γ-IND was very poor due to the morphology and size of particles 
(rectangular, sharp edged particles). Both carrier materials (SOL/XYL) pre-
sented free flowing powder behavior. Similar results have been shown 
previously (Seppälä et al., 2010; Reginald-Opara et al., 2015). 
When the amount of the carrier material was increased, the powder flow of 
the PMs significantly improved (Fig. 7). The PMs of γ-IND and SOL with the 
highest drug-polymer weight ratio (1:9) showed the highest powder flow rate 
(21.2 mg/movement), while the powder flow rate of the PMs (3:1) was the 
poorest (6.0 mg/movement) (Fig. 7). The 1:9 PMs (drug-sugar alcohol ratio) 
showed a good powder flow (20.0 mg/movement) and 3:1 PMs exhibited very 
poor powder flow (6.2 mg/movement) (Fig. 7).  
According to the literature, some established polymeric carriers (PVP, 
HPMC, chitosan) can advance the powder flow of crystalline IND in PMs 
(Yadav and Yadav, 2009). The powder flow of IND in these PMs was evidently 
improved due to the contact (drug particles) with round shaped polymeric/non-
polymeric carriers. Li et al. (2015) reported that the powder flow properties of 
paracetamol in PMs with SOL was improved since the drug crystals formed a 
thin coating layer on the surface of the polymer (SOL) particles (Li et al., 2015). 
The powder flow of the SDs of IND and SOL was superior compared to that of 
the corresponding PMs with the powder flow rate values of 17.6 mg/movement 
and 12.9 mg/movement, respectively (Fig. 7). This could be explained by the 
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larger average particle size and more spherical shape (oval) of the SDs com-
pared to that of PMs (Fig. 6). Djuris et al. (2013) showed that the SDs of SOL 
advanced the powder flow properties of carbamazepine. Dabbagh and 
Taghipour (2007) reported that the SDs of ibuprofen and PEG have superior 
powder flow properties over the corresponding PMs, and the authors suggested 
that SDs can be used for promoting the bulk powder flow of the drug. In the 
present study, the moisture content of SD (SOL) was somewhat smaller than 
that observed with the respective PMs (Fig. 8). Nevertheless, it is evident, that 
the difference in particle size and morphology is the major factor leading to the 
differences in the powder flow of SDs and PMs. 
 
Fig. 7. Powder flow of pure materials (γ-IND, SOL), physical mixtures (PMs) and quench 
cooled (QC) molten SDs with SOL (n = 3). Key: IND = indomethacin; SOL = Soluplus®. 
Reference materials for a powder flow test: Lactose 80M – 31.72 ± 1.31 mg/movement  
(= good flowability), Lactose 200M – 8.37 ± 0.27 mg/movement (= poor flowability) 
(dotted lines). 
 
 
6.2.4. Moisture content, sorption and wetting properties (II) 
The moisture content and wetting of pharmaceutical powders can essentially 
affect the bulk powder behavior, manufacturing, performance and stability of a 
final pharmaceutical dosage form. Fig. 8 shows the residual water content of 
pure materials, PMs and SDs. The water contents for the drug and SOL were 
0.24% and 2.49%, respectively. These results are in line with the values 
presented in the literature (Priemel et al., 2013b). The hydrophobic IND had a 
low water content, and this was verified also in the moisture sorption studies. 
SOL is an amorphous polymer known to be able to absorb water vapor from the 
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environment, and the polymer chains most likely interact more readily with 
water compared to XYL molecule (crystalline material). Different polymers 
behave differently, and the water may exist in different states within the 
material-bound vs free water which also affects the behavior of polymers in the 
presence of drug molecules (Williams et al., 2013). As shown in Fig. 8, the 
differences in the water content of PMs and SDs consisting of either SOL or 
XYL, are evident. With the PMs of γ-IND and SOL, the water content increased 
as the amount of polymer was increased (Fig. 8). The moisture content of the 
SDs of IND and SOL (1:3) was smaller than that observed with the respective 
PMs. Most likely this is due to the fact that within the glassy suspension of IND 
and SOL, the hydrogen bonding between the drug and polymer reduces the 
potential of H-bonding of the water to either component. 
Fig. 8. Water content (w/w %) of pure materials (γ-IND, SOL, XYL), physical mixtures 
(PMs), and quench cooled (QC) molten solid dispersions (SDs) (n = 3). Key: IND = 
indomethacin; SOL = Soluplus®; XYL = xylitol. The symbol (*) indicates the statistical 
significant difference (p ˂ 0.05). 
 
As expected, the moisture sorption of amorphous IND was found to be higher 
(1.3–2% increase in weight gain) than the moisture sorption of γ-IND. The 
corresponding increase in weight gain for SOL was 13–18%. The pure materials 
were exposed to high 95% RH for 7 days, but the equilibrium was reached 
already within 96 h. The PMs of IND and SOL (1:3) exhibited slightly higher 
values for weight gain (water vapor sorption) compared to the respective SDs. 
This result is in line with the water content measurement results. The moisture 
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sorption of SDs of IND and SOL (1:3) was much higher compared to that of 
pure IND forms (γ, α, amorphous IND). Most likely, the inclusion of SOL 
between IND molecules in regions of molecular-level mixing makes the interior 
of the SD particles more hygroscopic, thus resulting in increased water vapor 
uptake compared to pure forms. SOL containing PMs and SDs were less prone 
to water sorption. Punčochová and co-workers (2014) reported that the water 
sorption of SOL stored at 90% RH resulted in a 25% mass gain. In their study, 
the PMs and SDs of valsartan and SOL (1:3) were subjected to dynamic water 
sorption (0–95% RH). Interestingly, both PMs and SDs (the latter assumed to 
include molecular-level mixing) showed identical sorption isotherms with 
approximately 16% of a mass gain, which is in line with our findings. The reason 
for such phenomenon is obviously strong drug-polymer interactions and the 
blockage of H-bonding functional groups for water sorption. Nevertheless, the 
SDs showed faster dissolution (pH 6.8) kinetics than respective PMs 
(Punčochová et al., 2014). 
Formulating the drug in PMs and SDs usually results in improved wet-
tability, which is correlated with the improved intrinsic dissolution rate of the 
model drug (Chokshi et al., 2007). In the present study, the contact angle values 
for the SDs containing different carrier material were 54.9° ± 8.0 (IND and SOL 
1:3). The difference in contact angle values, however, were not statistically 
significant. It is evident that amorphous IND in the SDs absorbs water more 
readily compared to the crystalline γ- and α-IND (as verified in Fig. 9), thus 
resulting in decreased and more uniform contact angle values obtained with the 
SDs with different carrier materials (Fig. 9, II). 
 
 
Fig. 9. Moisture sorption of pure materials (γ-IND, amorphous IND, SOL), physical 
mixtures (PMs) and quench cooled (QC) molten solid dispersions (SDs) (n = 3). Key: 
IND = indomethacin; SOL = Soluplus®. 
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6.3. Quench-cooled molten solid dispersions of 
indomethacin and xylitol (I, II) 
6.3.1. Physical solid state and drug-carrier interactions (I)  
The DSC and MT-DSC thermograms of QC molten IND:XYL SDs showed two 
endothermic events (one for XYL at 89 °C and one for α-IND at 152 °C) and no 
change in Tg compared to pure materials, thus suggesting the presence of a 
poorly miscible two-phase drug-carrier system (Table 1, I). Since the 
recrystallization of IND was also detected at 124 °C, it is evident that XYL was 
not able to prevent the heat induced solid-state changes of IND in these SDs. 
Furthermore, also VT-XRPD results using IND:XYL SDs (Figs. 5C and D, I) 
verified the DSC/MT-DSC results showing a two-phase system (Fig. 4, I). 
The specific spectral regions of interest for the IND and XYL related 
interactions in SDs and PMs are at 1714 cm–1 and 1689 cm–1 (both C=O of 
IND) and 3421 cm–1, 3359cm–1, and 3293cm–1 (OH groups of XYL). The FT-IR 
spectra showed limited compatibility between those two components, since 
instead of the peak shift only intensity changes were detected in carbonyl and 
hydroxyl group vibrations. Several studies have shown limited ability of XYL 
to form chemical interaction with the active ingredients (Mummaneni and 
Vasavada, 1990; Sjökvist and Nyström, 1991; Suzuki and Sunada, 1997; Mad-
gulkar et al., 2015). 
 
 
6.3.2. Particle size, shape and surface morphology (I, II) 
Xylitol (XYL) possessed smaller agglomerates or particles with an uneven 
shape and size as amorphous IND and SOL (Figs 3, C, D, E). The average 
particle size of IND quench cooled (QC) molten mixtures of IND and XYL was 
alike to corresponding PM and SD of SOL. Interestingly, the larger particles in 
the PMs of γ-IND and XYL were layered with tiny drug particles (Fig. 10).  
 
 
Fig. 10. SEM micrographs of physical mixtures (PMs) and quench cooled (QC) molten 
solid dispersions (SDs). Key: B1 – PMs of γ-IND and XYL (1:3); B2 – SDs of IND and 
XYL (1:3). IND = indomethacin; XYL = xylitol. Magnification: ×500. Drug particles 
are indicated by arrows. 
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The corresponding micrographs of SDs containing IND and XYL at the weight 
ratio of 1:3 showed similar results, thus indicating that the drug particles were 
dispersed in a XYL matrix (Fig. 2C). 
 
 
6.3.3. Powder flow (II) 
The powder flow of XYL containing mixtures showed that it is a carrier driven 
process. As with SOL, those PMs of γ-IND and XYL with the highest drug 
polymer weight ratio (1:9) showed the highest powder flow rate, and the poorest 
flow with the highest drug loading (3:1). Sugars with a low water activity 
possess good powder flow properties (Seppälä et al., 2010). The powder flow 
properties of the SDs of IND and XYL (1:3), and the corresponding PMs were 
very similar (Fig. 11). This could be explained by the crystallization of XYL 
from the SDs resulting in the SD bulk powder with similar properties as PMs.  
 
 
Fig. 11. Powder flow of pure materials (γ-IND, XYL), physical mixtures (PMs) and quench 
cooled (QC) molten SDs with XYL (n = 3). Key: IND = indomethacin; XYL = xylitol. 
Reference materials for a powder flow test: Lactose 80M – 31.72 ± 1.31 mg/movement  
(= good flowability), Lactose 200M – 8.37 ± 0.27 mg/movement (= poor flowability) 
(dotted lines). 
 
The water content of the samples showed only small differences and moisture 
sorption was also alike. Indeed, the particles of the SDs were larger compared to 
those of the PMs, but the adhesion of IND particles to the surface of XYL 
particles in the PMs unified the surface roughness of the PM and SD particles. 
The particles with smooth surfaces were observed with both PMs (XYL) and 
SDs (XYL) (as shown in Fig. 10) which could explain their similar flow 
properties. According to the literature, the adhesion and friction forces between 
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the drug and carrier material are greatly dependent on the surface roughness of 
the particles (Podczeck, 1998). Genina and co-workers (2009) revealed that the 
particle surface engineering with an ultrasonic water mist improved the powder 
flow of lactose due to the particle surface smoothing and loss of fines. In the 
present study, it appeared that the inclusion of SOL or XYL in the PMs and SDs 
clearly promotes the powder flow of poorly flowing IND. It was found that the 
bulk powder flow properties of both PMs and SDs were directly related to the 
amount of carrier polymer used, and the SDs of the drug and carrier material 
presented equal powder flow as the corresponding PMs. In the PMs and SDs 
with XYL, drug particles were adhered or fused onto the surface of XYL, which 
unified also the powder flow of these systems. Moisture sorption most probably 
does not play any significant role in such systems, since XYL does not absorb 
much water below 80% RH (Rowe et al., 2009). 
 
 
6.3.4. Moisture content, sorption and wetting properties (II) 
The water content for XYL was 0.42%. XYL is a small-molecule nonporous 
sugar alcohol, and it possesses much lower water content due to its crystalline 
structure. With the PMs of γ-IND and XYL, the water content was virtually 
independent of the amount of the carrier used (Fig. 6). With the SDs of IND and 
XYL (1:3), the moisture content was higher (0.52%) compared to that of PMs 
(0.35%). This small difference in water content could be explained by the more 
hygroscopic nature of amorphous IND dispersed in a crystalline hydrophilic 
XYL matrix in two-phase SDs (amorphous precipitation system). Since the 
surface of the PMs and SDs of IND and XYL samples was covered with drug 
particles (confirmed by SEM, Fig. 10), the adsorption of water on crystalline 
XYL is most likely largely depended on the solid state of the drug. The 
moisture studies showed a significant weight gain for XYL (34–89%). XYL 
was rapidly absorbing moisture for up to 144 h (89%). As seen in Fig. 12, the 
SDs of IND and XYL (1:3) showed a similar weight gain (water vapor sorption) 
as its respective PMs. SDs containing XYL showed highly hydrophilic 
properties, with contact angle of 46.4° ± 5.7 (IND and XYL 1:3). Rapid changes 
in the weight gain of both PM and SD samples occurred within the first 24 h 
(25.2–35.5% increase in weight gain). The SDs of IND and XYL (1:3) 
dissolved partially in sorbed water and formed transparent droplets. According 
to the literature, the water sorption of sugars ranges typically 3–5 mg/g, and 
water activity (aw) of XYL is 0.6 (25 °C) (Weisser et al., 1982). At the aw levels 
of 0.6–0.7, water molecules are adsorbed on the crystal surface, but at the aw 
values higher than 0.7, the amount of absorbed water rises steadily resulting in 
the dissolution of the crystals (Demertzis et al., 1989). As IND and XYL were 
in two separate phases in both SDs and PMs, the overall effect of the hydro-
phobic small molecule on the moisture sorption was negligible. In summary, the 
PMs and SDs of IND with XYL can sorb water vapor more readily compared to 
the corresponding PMs and SDs of IND with SOL. 
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Fig. 12. Moisture sorption of pure materials (γ-IND, XYL), physical mixtures (PMs) 
and quench cooled (QC) molten solid dispersions (SDs) (n = 3). Key: IND = indo-
methacin; XYL = xylitol. 
 
 
6.4. Melt-electrospun fibrous solid dispersions of 
indomethacin and Soluplus® (III) 
6.4.1. Physical solid state and drug-carrier interactions (III) 
The XRPD was used to detect physical solid-state changes of the components in 
a MES process. The list of prepared formulations are depicted in Table 3. The 
drug (IND) in the PM1 preserved its γ-IND crystalline form after mixing with 
SOL (a slightly elevated baseline of amorphous SOL can be also seen). As 
expected, the PM of amorphous IND and SOL (PM2) showed only an 
amorphous halo. In case of the PM3 (the PM was stored at RH 90%), the XRPD 
pattern showed minor intensity changes, but the γ-IND reflections were clearly 
distinguishable. The polymorphic transformation of an amorphous IND to  
α-IND, however, was not detected at high RH in the present study, and this 
finding differs from the results on the physical stability of IND reported in the 
literature (Shalaev and Zografi, 2002). Evidently, the addition of polymer 
(SOL) can significantly alter the crystallization behavior of an amorphous 
material. The MSFs of IND and SOL (originated from the PM3) showed the 
XRPD pattern with a clear amorphous halo, thus confirming the formation of an 
amorphous SD (Fig. 4, III). 
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Table 3. Formulations used in melt-electrospinning (MES) studies 
Formulations Composition 
PM1 physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 
(drug:polymer) 
PM2 physical mixture of amorphous IND and SOL at the weight ratio 1:3 
(drug:polymer) 
PM3 PM1 stored at high RH (90%) 
MSF  melt-electrospun fibers prepared from PM3 
Key: PM – physical mixture, MSF – melt-electrospun fiber, SOL – Soluplus®, RH – relative 
humidity.  
 
FTIR, spectroscopy was used to investigate the potential drug-carrier polymer 
interactions during MES. In the present study, a special attention was paid to the 
region between 1650 cm–1 and 1750 cm–1 which is characteristic to IND 
carbonyl (C=O) stretching bands (Ewing et al., 2014). As seen in (Fig. 5, III), 
the FTIR spectrum of γ-IND contains two bands in this region. The peaks at 
1688 cm–1 and 1711 cm–1 were assigned to the benzoyl C=O and assymetric 
stretch of the carbocylic acid bands, respectively. The present results are in 
accordance with the wavenumbers reported for C=O bands in the literature 
(Ewing et al., 2014; Lin et al., 2015; Terife et al., 2012). The spectra of PM1 
and PM3 are quite similar. Both contain the benzoyl C=O vibration band at 
1688 cm–1. Due to spectral overlapping with the SOL ester C=O band at 1732 
cm–1, the band assigned to assymetric stretch of the carbocylic acid is located at 
1715 cm–1 in the spectra of PM1 and PM3. The benzoyl C=O vibration band 
appears at 1682 cm–1 in the spectra of MSFs and PM2. According to the 
literature, the band at this wavenumber is specific to amorphous IND (Ewing et 
al., 2014; Lin et al., 2015; Terife et al., 2012). The spectrum of PM2 contains a 
shoulder to the SOL ester C=O band at 1709 cm–1 that has been assigned to the 
hydrogen bonded carboxylic acid C=O in amorphous IND molecules arranged 
as chains or dimers (Ewing et al., 2014; Lin et al., 2015; Terife et al., 2012). 
This feature is lacking in the spectrum of MSFs. This difference in the spectra 
could indicate at least partial hydrogen bonding between IND and SOL 
molecules in MSFs. 
We also recorded the 1H-spectra of PM1 and MSFs which were recorded 
after dissolving the materials in deuterochloroform. The NMR spectra of 
electrospun mixture includes a combination of IND and SOL chemical shifts, 
thus confirming the lack of thermal degradation (Fig. 13A).  
13C FT-NMR spectroscopy (13C CP-MAS-spectra) was carried out to study 
more intimate mixing of the drug:carrier (SOL) and their chemical stability. 
13C-CP-MAS-spectrum of the PM1 shows the chemical shifts of both 
substances as a direct superposition of the spectra of the pure materials (Fig. 
13B). In the PM1, IND is still in the γ-form as indicated by the lack of splitting 
of the signals (Masuda et al., 2006). For the MSFs, the chemical shifts show a 
marked change as in general the signals from γ-IND are broadened significantly 
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and nearby signals are merged together. As the signals from pure SOL are 
already quite broad, similar changes were not observed for SOL in MSFs. This 
change in the IND spectrum suggests more intimate mixing of the substances 
during a MES process (Fig. 13B).  
 
 
Fig 13. Overlay of 1H-spectrum of physical mixture (PM1) and melt-electrospun fibers 
(MSFs) (A) and 13C CP-MAS-spectra of starting materials, physical mixture (PM1) and 
melt-electrospun fibers (MSFs) (B). Key: γ-IND – indomethacin, SOL – Soluplus®, 
PM1 – the physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 
(drug:polymer), MSF – melt-electrospun fibers prepared from PM3 (the PM1 stored at 
high RH (90%). 
 
In order to get more information about the difference of IND in the PM1 and 
MSFs, the relaxation time T1(1H) was recorded. Signals in the approximate 
region of 63–76 ppm originate exclusively from SOL and 125–138 ppm from 
IND. The measured T1(1H) of SOL (63–76 ppm) is 2.061 s for the PM1 and 
2.067 s for the MSFs, and they can be considered to be practically the same. 
However, the measured T1(1H) of IND (125–138 ppm) in the PM is 4.524 s 
compared to that of 2.165 s for the MSFs. This gives IND a domain size range 
of 25–100 nm for the MSFs. The very similar values of T1(1H) for both IND 
and SOL in the MSFs can be considered as a strong indication of significantly 
smaller domain size of the IND in the SOL matrix compared to the PM1. The 
T1ρ1H, which would give information about the domain size within the range of 
2–20 nm, could not be measured as the long spin-lock times would have 
seriously damaged the probe.  
 
 
6.4.2. Fiber diameter, shape and surface morphology (III) 
The fiber size and morphology of drug-loaded melt-electrospun fibers (MSFs) 
of IND and SOL at the weight ratio of 1:3 and the corresponding blank MSFs 
are presented in Fig. 14. The diameter of drug loaded MSFs ranged from 
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300 µm to 400 µm and the diameter of blank MSFs ranged from 200 µm to 
400 µm. As reported elsewhere, the diameter of fibers prepared by MES can 
vary even from 270 nm (i.e., nano-scale) to 500 µm (micro-scale) (Dalton et al., 
2006; Lyons et al., 2004). Such a wide size range option in fiber diameters 
shows the flexibility of MES. In the present study, the large micro-scale size of 
MSFs could be explained by the high molecular weight of SOL (90 000 – 
140 000 g/mol) (BASF, 2010). According to the literature, the molecular weight 
of a thermal carrier polymer is a critical factor determining the final fiber 
diameter in MES (Lyons et al., 2004).  
Fig. 14. The SEM images of (A1) intact melt-electrospun fibers (MSF) of γ-IND and 
SOL at the weight ratio of 1:3 (drug to polymer), (A2) the corresponding ground MSFs, 
(B1) blank MSFs, and (B2) the corresponding ground blank MSFs. Key: γ-IND = 
indomethacin, SOL = Soluplus®. 
 
The surface morphology of the present MSFs (Fig. 14) was smooth without any 
voids or pores, but clearly shrunken and billowy for the whole fiber area. This 
could be explained by a thermal shock induced by the temperature difference 
during MES when the fibers are produced and collected. The shrinking was 
more pronounced with blank MSFs (Fig. 14B), thus showing a higher polymer 
chain mobility compared to the drug loaded MSF. It is well known that higher 
surface area results in higher dissolution rate (Noyes and Whitney, 1897). 
Hence the major advantage of shrunken and billowy MSFs compared to the 
smooth fibers is a larger specific surface area, and thus their dissolution rate 
should be faster compared to the smooth surfaced fibers/particles. 
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The SEM image on the cross-section of drug-loaded MSFs (Fig. 14A1) 
shows a non-uniform structure of the fiber. At some places, the fibers are hollow 
and at others they do not have any inner voids at all. The cross-section of blank 
fiber (as shown in Fig. 14B1) consisted of primarly intact solid surface with 
very small voids. The difference in the fiber morphology of the drug-loaded and 
blank MSFs could be related to the different molecular mobility and rigidity of 
the IND containing SOL and pure SOL during MES process. As mentioned 
earlier, the instability of a MES process could also partially explain the for-
mation of MSFs with such a complicated structure. Fig. 14 shows also the SEM 
images of drug-loaded (A2) and blank (B2) MSFs in a powder form after 
grinding. The partially hollow structure of the original MSFs can be still seen 
even after grinding (Fig. 14A2). These cavities are evidently the former water 
vapor channels inside a fiber matrix, and they are formed as water is evaporated 
from the matrix or extrudate (Miladinov and Hanna, 1999). 
 
 
6.4.3. Moisture content (II) 
Due to the high viscocity of the melt, it was necessary to decrease the tempera-
ture of the process to avoid the chemical degradation of the drug (IND) and 
carrier (SOL). Pre-storing the samples at high humidity (above 90% RH) in 
dessiccator prior MES experiments was used in order to plasticize the PM1. The 
latter enabled to lower the processing temperature of MES by 40 °C (to 180 °C). 
Hence, the addition of plasticizer (in our case water) was of critical importance. 
In addition, water vapor heated up to 180 °C created additional pressure that 
probably helped to overcome the high viscosity of the polymer melt. 
In our system, water acted as a plasticizer reducing the viscosity of the melt 
and improving the performance of a MES. The plasticizing effect of water has 
been previously shown for starches prior extrusion into the foams (Shogren, 
1996; Sjöqvist and Gatenholm, 2005). In the case of starch extrusion, water 
added in the system is entrapped inside the cavities of the extrudate, and after 
leaving extruder, it evaporates and forms channels in the matrix (Miladinov and 
Hanna, 1999). It is evident that similar interaction with water also occurs in the 
present MES process, thus resulting in the formation of partially hollow MSF 
structures.  
 
 
6.4.4. Chemical and thermal stability (III) 
Like in HME, on the course of MES the materials are subjected to a short-term 
high temperature and pressure during the process. These conditions can cause 
the chemical degradation of drug, polymer or both. According to the literature, 
thermal decomposition of IND is a one-step phenomenon within the range of 
236–338 °C (Tita et al., 2009). IND has a good safety margin for thermal pro-
cessing at lower temperatures. According to Forster et al. (2001), the chemical 
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stability of IND in PVP/IND dispersions at different weight ratios (1:1 and 4:1) 
after HME at 170 °C was good, since only less than 1% of drug was decomposed. 
Melt extrusion of acrylic polymers/IND (30% drug concentration) showed that 
IND is chemically stable after exposure to high temperature (140 °C) (Zhu et 
al., 2006). SOL is thermally stable up to 220 °C showing no changes in the 
chemical composition or degree of polymerization (BASF, 2010; Kolter et al., 
2012). Weight loss of the samples up to 150 °C was assigned to the desorption 
of water. Given values were used to estimate the amount of water absorbed by 
SOL and PMs. SOL contained 2.37% and the PM1 contained 1.56% of water by 
weight. After storage at high RH (90%), the PM3 contained 7.41% of water by 
weight. IND was found to be a thermally stable compound at the temperature 
that was used for MES (only 0.11% of weight loss at 180 °C was detected). The 
thermal degradation of IND and SOL started at 197.1 °C and 218.2 °C, 
respectively. According to the literature, the thermal degradation of IND occurs 
approximately at 236 to 338 °C (with Tmax 314 °C) (Tita et al., 2009). The 
present results are in agreement with those reported in the literature, where a 
2.5% weight loss of SOL was detected at low temperatures, and the degradation 
of the material started approximately at 250 °C (Kolter et al., 2012). In 
summary, TGA results suggest that MES performed at 180 °C is a non-
destructive process and does not cause (or causes only minimal) thermal 
degradation for the present materials. A long-term exposition of materials to 
MES process, however, will most likely result in thermal degradation of the 
materials. 
The TGA results were in line with the DSC results, where γ-IND showed a 
sharp melting endotherm at 161.8 °C (without any water desorption), and SOL 
showed a broad water evaporation endotherm until 76.3 °C (indicating also a 
substantial amount of water in the samples) (Fig. 15, B). The DSC thermo-
graphs of PM1 showed broad water evaporation endotherm derived from SOL 
within PMs and a broad fusion endotherm of γ-IND into SOL starting 
at 115.7 °C. The fusion endotherm ended with a minor sharp endotherm at 
160.1 °C, which was attributed to the melting of residual γ-IND. The PM2 
containing amorphous IND and SOL at the weight ratio 1:3 (drug:polymer) 
presented the Tg of IND at 50.6 °C and a water evaporation endotherm. In 
addition, a small exothermic peak was recorded at 83.8 °C, and it was assigned 
to the crystallization of IND. The onset temperature of the subsequent fusion 
endotherm for recrystallized IND was recorded at 107.0 °C. The PM3 (stored at 
high RH 90%) thermogram mirrored the results of PM1. As expected, the 
thermal behavior of PMs revealed the behavior of the pure materials alone 
(Fig. 15, B). The DSC thermograph of MSF indicates the formation of amorp-
hous SD, since no signs of the IND melting point were detected, which 
obviously indicated at least partial mixing of a drug in a molten polymer 
(Fig. 15, B). 
Total drug content of MSFs after preparation was assayed/verified by HPLC. 
Three different MES batches were analysed in duplicate or triplicate (theoretical 
drug content was 25%). The following drug content for different MSF batches 
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were measured: 23.2 ± 0.15% (n=3) for batch 1; 23.8 ± 0.6% (n=3) for batch 2 
and 23.5 ± 0.4% (n=2) for batch 3. These values were in close proximity to the 
theoretical drug content values confirming that the present MES process is 
stable and reproducible resulting in small drug content variation. 
 
Fig. 15. Thermogravimetric analysis (TGA) (A) and differential scanning calorimetry 
(DSC) thermograms (B) of starting materials, physical mixtures (PMs) and melt-
electrospun fibers (MSF). Key: γ-IND – indomethacin, SOL – Soluplus®, PM1 – the 
physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 (drug:polymer), 
PM2 – the physical mixture of amorphous IND and SOL at the weight ratio 1:3 
(drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-electrospun 
fibers prepared from PM3. The actual process temperature of MES (180 °C) is indicated 
with a solid line in the figure. 
 
 
6.5. Dissolution in vitro (II–III) 
The BCS deploys IND among the class II drugs, which are characterized by 
slow or partial dissolution and fast absorption in vivo (Amidon et al., 1995). 
Accordingly, with the BCS class II drugs dissolution is a critical attribute 
governing their oral bioavailability and therapeutic effect. Craig (2002) reported 
that the dissolution of drug-loaded SDs can be primarily either (1) the carrier-
controlled dissolution (especially at low drug loadings), or (2) drug-dependent 
dissolution. The prevalence of the release mechanism is dependent on the 
miscibility and solubility of the components in the concentrated solution of the 
polymer (Craig, 2002). In addition, several processes competing with one 
another take place simultaneously during the dissolution of SDs, and both the 
drug and carrier polymer properties affect the total drug release (Kogermann et 
al., 2013). 
We found that the SDs of IND and SOL form a two-phase glassy suspension 
where the amorphous IND is thoroughly mixed with amorphous SOL (Fig. 2). 
This enhanced dissolution is obviously as a result of improved wetting of IND 
and inhibited crystallization of the drug from amorphous form or from solution 
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to α form by SOL. Futhermore, over 85% of the drug was released from the SDs 
of IND and SOL within 60 min of the dissolution test (Fig. 16). According to 
Surwase et al. (2015), molecular mixing between IND and SOL in one-phase 
SD completely inhibited the drug release. Interestingly in the present study, the 
release of IND from the corresponding PMs was hindered due to the gelling 
properties of the polymeric carrier and very poor wettability of PMs and γ-IND 
(Fig. 5). Since γ-IND is hydrophobic, the amphiphilic SOL molecules tend to 
adhere onto the IND crystals, thus decreasing the effective dissolution surface 
area. The present results are consistent with the earlier studies showing that the 
PMs of IND and SOL exhibit a slower dissolution rate because of the gel 
formation and strong H-bonding (Terife et al., 2012).  
According to the results, the SDs of IND and XYL are two-phase systems in 
which IND is in amorphous form in a crystalline XYL matrix (Fig. 2). The drug 
release was improved with XYL containing PMs and SDs (Fig. 16) without 
reaching plateau as with SOL SDs. Excipient intrinsic properties are of critical 
importance in enhancing the solubility and dissolution rate of PWS drugs. Most 
likely on the course of rapid dissolution of XYL, the IND particles did not 
adhere to each other and higher effective surface area was achieved. XYL as a 
carrier material is freely water-soluble polyalcohol with no gel forming ability 
(Rowe et al., 2009). 
The MSFs of IND and SOL were prepared to assess their drug releasing 
behavior and compare with to the respective QC SDs. It was found that the 
dissolution rate of MSFs and PM2 (amorphous IND) was significantly higher 
than that of crystalline γ-IND powder (Fig. 16). The PM1 showed the slowest 
drug release, probably due to gel formation of the polymer (SOL). Almost 
complete drug release of MSFs was observed within 30 min (88.7±0.5%), while 
the dissolution of drug released from crystalline drug and respective PMs was 
much slower and limited. The improved release rate of IND from MSFs is 
evidently due to the amorphous state and smaller domain size of IND compared 
to PM1 and PM2. Furthermore, MSFs in a powder form provide a higher effec-
tive surface area compared to other solid state forms. This is due to a specific 
morphology of the powder particles obtained by grinding the present MSFs 
(i.e., partially plate shaped particles). These properties have been reported to 
have a significant effect on the release rate of PWS drugs (Hancock and Parks, 
2000; Hughey et al., 2013; Merisko-Liversidge and Liversidge, 2011). These 
observations are in accordance with those reported by Balogh et al. (2014) and 
Nagy et al. (2013), who found that the drug release of MSF is comparable to the 
fibers fabricated by solvent-based ES and superior to PMs and drug alone 
(Balogh et al., 2014; Nagy et al., 2013). 
Drug dissolution rate from MSFs was higher than from QC SDs or respec-
tive PMs. The XYL containing PMs showed different release profile but by 
60 min the total amount of drug in the solution was similar to MSF. Our 
findings suggest that MES can be viable option for improving the solubility of 
PWS drugs and regarded as alternative SD preparation technique to QC and 
HME. 
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Fig. 16. In vitro dissolution profiles of γ-IND, physical mixtures (PMs) and melt-
electrospun fibers (MSF) at the weight ratio 1:3 (drug:polymer) in pH 6.8 phosphate 
buffer (n=3). Key: γ-IND – indomethacin, PM1 – the physical mixture of crystalline  
γ-IND and SOL at the weight ratio 1:3 (drug:polymer), PM2 – the physical mixture of 
amorphous IND and SOL at the weight ratio 1:3 (drug:polymer), PM3 – the physical 
mixture of amorphous IND and SOL at the weight ratio 1:3 (drug:polymer) stored at 
90% RH, QC SOL – quench cooled solid dispersion of IND and SOL at the weight ratio 
1:3 (drug:polymer), QC XYL – quench cooled solid dispersion of IND and XYL at the 
weight ratio 1:3 (drug:polymer), MSF – powdered melt-electrospun fibers. The error 
bars indicate the standard deviations (n = 3). 
 
 
6.6. Physical storage stability of solid dispersions (I) 
According to the literature, molecularly dispersed single-phase solid dispersions 
(SDs) are the most stabilized systems against crystallization (Williams et al., 
2013). Hence, the degree of miscibility between the drug and polymer is 
important for the formation of a physically stable amorphous system. Aging 
under different humidity conditions can change the physical solid-state pro-
perties and performance of two-phase SDs systems. In the present study, the 
physical stability of the two-phase systems was investigated to understand their 
potential stabilizing mechanisms (I). The physical storage stability of the aged 
QC molten SDs of IND:SOL and IND:XYL was investigated by means of 
XRPD, DSC and ATR-FTIR spectroscopy. Interestingly, different analytical 
methods revealed somewhat different level of physical stability in these two-
phase SD systems, thus providing a futher proof that complementary analysis 
methods are needed to obtain complete insight into the complex recrystalli-
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zation behavior. According to XRPD, the QC molten SDs (with a IND:SOL 
weight ratio of 1:3) were stable up to 2 months when stored at 0% RH/RT, and 
at least 1 week when stored at 50% RH/RT (no sign of recrystallization 
observed). However, storing the present SDs at 75% RH/RT provided only 
temporary stability. Due to the high noise and low intensity, it was very difficult 
to fully confirm the origin of the present IND reflection by XRPD (the peak is 
in close proximity of both γ- (21.8° 2θ) and α-IND (22.0° 2θ). The DSC results 
revealed that a partial recrystallization of α-IND during storage was observed 
(melting endotherm at 153 °C). According to Andronis et al (1997), amorphous 
IND stored at 30 °C and 56% RH crystallized into α-IND and amorphous IND 
stored at 0% was stable at least for 100 days. Whilst during storage at tempera-
tures below the Tg and at low RH usually the recrystallization of γ-IND is 
favored and above Tg and high RH metastable α-IND is formed (Shalaev and 
Zografi, 2002). It is known that the method of preparation as well as the 
presence of stabilizing molecule may change the physical stability of IND 
samples (Vasconcelos et al., 2007; Surwase et al., 2015). With two-phase 
amorphous SDs, the level of miscibility (like with one-phase systems), steric 
hindrance and reduced interface molecular mobility are crucial affecting the 
physical stability. It has been shown with the PMs of Eudragit® E and pure 
amorphous IND that the polymer reduces the molecular mobility and possibly 
mechanical obstruction at the surface of amorphous IND, thus stabilizing 
amorphous IND (Priemel et al., 2013a). However, due to the large particle size 
differences between the drug and polymer (SOL), SOL was unable to cover the 
surface of IND and inhibit its surface-biased nucleation and growth at low RH 
(22%, 43% RH) and temperature (Priemel et al., 2013a). More recently, 
Surwace and co-workers (2015) investigated the physical stability of amorphous 
IND in aqueous suspension with different polymers. The SD of IND and SOL 
showed the latest crystallization onset (>28 days) compared to other systems, 
which was explained by the reduced molecular mobility of SD (higher Tg) 
compared to pure amorphous IND, and by formation of hydrogen bonding or 
other intermolecular interactions between the components (Surwase et al., 
2015). The prepared two-phase IND:SOL SDs showed that two amorphous 
components with different Tg have separate phases, but are stable enough to 
prevent the surface-based crystallization at least at low RH. Most likely, the 
same stabilization mechanism (as described by Surwase and co-workers) 
governs and plays an important role with our SDs as well. It is possible that 
some hydrogen bonding interactions between amorphous IND and SOL in the 
QC molten two-phase amorphous SDs were present thus stabilizing the SDs. 
However, the stability of a two-phase system may be associated to physical 
stabilization of multiple phases. 
The physical stability of QC molten IND:XYL SDs (50% RH/RT) was very 
limited. It has been shown that the co-milling of IND and aminoacids (eg., low 
molecular weight molecules), results in stable co-amorphous systems which are 
physically stable up to 6 months of storage at 40 °C (Löbmann et al., 2013). 
However, in the present study two-phase amorphous precipitation system was 
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obtained instead of co-amorphous form with specific molecular interactions. For 
our two-phase SDs amorphous suspensions, the proposed stabilization mecha-
nisms are as follows: (1) Internal stabilization, where amorphous IND rich 
phase is contaminated with SOL leading to reduced molecular mobility due to 
increased local viscosity. With IND:XYL SD where amorphous drug was 
precipitated in a crystalline matrix, this is not so evident. The phase contami-
nation in IND:SOL SD was confirmed by the change in Tg compared to pure 
materials. (2) Interface stabilization which could be related to the hydrogen 
bond formation at the phase boundary between the drug-polymer, thus pre-
venting crystallization by the formation of drug-drug interactions. In case with 
SOL, it has functional groups (C=O and –OH) with capacity to bind to IND. 
Drug XYL combination has limited functional groups and bone rigidity to 
support the intermolecular interaction within the system. Priemel and co-
workers (2013a) have shown that IND crystallized from the surface at 
temperature below Tg, and reduced molecular mobility at the surface and 
mechanical inhibition can improve the physical stability.  
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7. SUMMARY AND CONCLUSIONS 
The QC molten two-phase SDs of a PWS drug indomethacin with two different 
matrix formers (amorphous copolymer vs crystalline sugar alcohol) exhibit 
significant differences in particle properties and bulk powder behavior. Both 
carrier materials studied here can advance the powder flow properties of a 
cohesive IND powder, and this improvement is directly related to the amount of 
a carrier material used in PMs or SDs. The inclusion of a carrier material 
(SOL/XYL) in both PMs and SDs improves also the wetting properties of an 
IND powder, where XYL mixtures showed higher moisture sorption compared 
to SOL ones. The in-vitro drug release of the present SDs and PMs has a 
carrier-controlled release mechanism at pH 6.8. The enhanced drug dissolution 
from the SDs with SOL is due to improved wetting and inhibited crystallization 
of IND. XYL as a freely water-soluble polyalcohol advances the dissolution rate 
of IND most likely through improving the wetting properties and providing the 
hydrophilic environment in the solution.  
Furthermore, it was shown that MES is an auspicious novel method for 
fabricating amorphous SDs for PWS drug. Only minimal thermal degradation of 
a model drug (IND) is associated with the fabrication of MSFs in a MES 
process. Solid-state analysis suggests more intimate mixing between IND and 
an amorphous stabilizing carrier material (SOL) in the present MSFs. The 
MSFs of IND and SOL provided significantly faster drug dissolution compared 
to QC SDs, corresponding PMs and crystalline drug.  
In summary, the MSFs produced by MES could be an alternative strategy to 
traditional or modified QC and HME in improving the dissolution, and con-
sequently the oral bioavailability of PWS drugs. Further studies are needed to 
confirm if current findings would lead to better absorption rate and bioavaibility 
in vivo.  
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SUMMARY IN ESTONIAN 
Vees halvasti lahustuva indometatsiini tahkete dispersioonide 
valmistamine farmatseutilisel eesmärgil sulami kiirjahutamisel ja 
sulami elektrospinnimisel 
SISSEJUHATUS 
Farmatseutilise ravimvormi disain ja väljatöötamine vajab laiahaardelisi eri-
alaseid teadmisi ja tausta teavet. Tööprotsess algab haiguse identifitseerimisest, 
toimeaine leidmisest, järgnevad farmakoloogilised/toksikoloogilised uuringud, 
preformulatsiooni uuringud ja ravimvormi disain ning valmistamine. Kui 
prekliinilised uuringud on andnud positiivseid tulemusi, siis järgnevad kliini-
lised uuringud, kus tõestatakse ravimpreparaadi ohutus ja efektiivsus. Välja on 
töötatud regulatoorsed juhendid farmaatsiatööstusele, et toetada ravimprepa-
raatide väljatöötamist ning tagadaravimpreparaatide kvaliteeti, ohutust ja efek-
tiivsust (CDER/FDA, 2015; CDER/FDA, 2007; ICH 2015). Näiteks laiaulatus-
likud dissolutsioonitestid ja stabiilsuskatsed on vajalikud eduka toote välja-
töötamiseks ja selle järgnevaks turule laskmiseks. 
Suukaudne manustamine on jätkuvalt peamine ravimite kasutamise viis. See 
on lihtne, kiire, mugav ja valutu võimalus erinevate ravimvormide võtmiseks, 
tehes sellest kõige atraktiivsema ravimite manustamisviisi patsientidele . Samuti 
on tahke suukaudsed ravimvormid ühed levinumad ja lihtsamad valmistada ka 
farmaatsiatööstusele. Vesilahustuvus ja gastrointestinaalne permeaabelsus on 
teadaolevalt ühed võtmeparameetrid kontrollimaks toimeaine lahustuvuse ja 
imendumise ulatust organismis. Lähtuvalt Biofarmatseutilisest Klassifikatsiooni 
Süsteemist (BCS) ja eelpool nimetatud parameetritest, on ravimid jaotatud nelja 
rühma: hea lahustuvus-hea permeaabelsus (BCS I); halb lahustuvus-hea per-
meaabelsus (BCS II); hea lahustuvus-halb permeaabelsus (BCS III); ja halb 
lahustuvus-halb permeaabelsus (BCS IV) (Amidon et al., 1995). Kirjanduse 
andmetest lähtuvalt, ainult 5% uutest toimeainetest kuuluvad BCS I klassi ning 
90% on klassifitseeritud kui halvasti lahustuvad (BCS II ja BCS IV) toimeained 
(Williams et al., 2016). On näidatud, et 75% toimeainetest väljatöötamise faasis 
või tootmise faasis klassifitseeritakse kui vees halvasti lahustuvad toimeained 
(Di et al., 2009). Uudsete ravimvormide, ravimkandursüsteemide ja abiainete 
väljatöötamine ja tootmine võimaldab, parandada toimeainete vesilahustuvust, 
lahustumiskiirust ja seega ka vees halvasti lahustuvate toimeainete biosaadavust 
organismis.  
Antud väitekirja hüpoteesiks on, et erinevate meetoditega valmistatud vees 
halvasti lahustuva toimeaine indometatsiini (IND) ja Soluplus®-i (SOL) ja/või 
ksülitooliga (XYL) tahked amorfsed dispersioonid tõstavad IND lahustusmi-
kiirust ja võimaldavad stabiliseerida tema amorfset vormi. SOL on uudne kopo-
lümeer, mis oli esialgselt väljatöötatud kasutamiseks sulami-ekstrusioonis 
(BASF, 2010). XYL on suhkur polüool, mis alles hiljuti on leidnud kasutamist 
ka farmatseutilise abiainena (Rowe et al., 2012). Koos solvendi aurustumise 
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meetodiga on sulami-kiirjahutamine üheks traditsiooniliseks tahkete disper-
sioonide valmistamisemeetodiks. Sulami-elektrospinnimist võib käsitleda tradit-
sioonilise sulatamise/kokku-sulatamise edasiarendusena tahkete dispersioonide 
valmistamisel. Sulami-elektrospinnimine on üheks uudseks võimaluseks kaas-
aegsete ravimkandursüsteemide arendamisel vees halvasti lahustuvate toime-
ainetele. Käesolevas väitekirjas uuriti erinevate abiainetega (SOL/XYL) kiir-
jahutatud amorfsete tahkete dispersioonide olulisi füsikokeemilisi omadusi ja 
toimeaine vabanemist ning tema stabiilsust. Uuriti sulami elektrospinnimise teel 
valmistatud ainulaadsete omadustega fiibreid, kus võtmeküsimus oli, kas antud 
omadused parandavad toimeaine lahustumiskiiruse ja antud ravimvormi füsiko-
keemilist stabiilsust. Töö tulemused näitasid, et sulami-elektrospinnimisel 
saadud vees halvasti lahustuva toimeainega (indometatsiin) fiibrid on füsiko-
keemiliselt stabiilsed ja tagavad toimeaine kiire vabanemise ja lahustumise. 
 
 
EESMÄRGID 
Antud väitekirja eesmärgiks oli aru saada kahe termilise tahke dispersiooni 
valmistamise meetodi ja kahe erineva abiaine mõjust vees halvasti lahustuva 
toimeaine indometatsiini (IND) füsikokeemilistele omadustele. Erilist tähele-
panu pöörati just amorfsetes tahketes dispersioonides oleva toimeaine füüsika-
lise stabiilsuse ja toimeaine vabanemise- ja lahustumiskiiruse uuringutele.  
Töö täpsemad eesmärgid: 
‒ Uurida tahke aine vormi ja selle füüsikalist stabiilsust sulami-kiirjahutamisel 
valmistatud tahketes dispersioonides kahe maatriksit tekitava abiainega 
(SOL/XYL) (I). 
‒ Uurida sulami-kiirjahutamisel valmistatud kahefaasiliste tahkete dispersioo-
nide osakese ja pulbri taseme omadusi, märgumist ja toimeaine vabanemis- 
ja lahustumiskiirust (II). 
‒ Võrrelda polümeerse ja kristallilise abiaine mõju tahkete dispersioonide 
omadustele (nii molekulaarse taseme kui osakese ja pulbritaseme oma-
dustele) ja selle mõjust toimeaine vabanemisele ja lahustumisele tahketest 
dispersioonidest (II). 
‒ Valmistada sulami-elektrospinnimisel amorfne tahke dispersioon fiibris 
parandamaks vees halvasti lahustuva toimeaine lahustumiskiirust (III). 
‒ Aru saada sulami-elektrospinnimisel valmistatud fiibris oleva toimeaine 
tahke aine vormi füüsikalistest muutustest, toimeaine-polümeerse abiaine 
vahelisest interaktsioonidest ja toimeaine lahustumiskiirusest (III). 
 
MATERJALID JA MEETODID 
‒ Füüsikaliste segude ja tahkete dispersioonide valmistamine 
 Füüsikalised segud valmistati erinevates toimeaine-abiaine vahekordades 
(3:1, 1:1, 1:3, 1:6, 1:9), mida kasutati tahkete dispersioonide võrdlusena. 
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Mudel toimeainena kasutati indometatsiini (IND). Abiaineteks valiti amorfne 
polümeer SOL ja kristalliline XYL. Modifitseeritud sulami kiirjahutamine 
toimus toimeaine ja polümeeride sulatamisel ja järgneval jahutamisel vedela 
lämmastikuga. Sulami-elektrospinnimine viidi läbi kõrge niiskuse juures 
(˃90%) säilitatud mudel toimeaine ja SOL-i füüsikalise seguga. Võrdluseks 
valmistati toimeaine vaba puhta polümeeriga fiiber.  
‒ Morfoloogiline ja topograafiline analüüs 
 Skaneerivat elektromikroskoopi kasutati morfoloogiliseks ja topograafiliseks 
analüüsiks. Uuriti puhtaid aineid, füüsikalisi segusid ja tahkeid dispersioone 
valmistatud sulami-kiirjahutamisel.  
‒ Kristallograafia 
 Pulber-röntgendifraktomeetriat kasutati tahke faasi määramiseks. Uuriti 
mudeltoimeainet, abiaineid (SOL, XYL), füüsikalisi segusid ja tahkeid dis-
persioone. Eesmärgiks oli kindlaks määrata toimeaine amorfne vorm tahketes 
dispersioonides võrreldes difraktogramme vastavate füüsikaliste segudega. 
‒ Pulbri voolavus, niiskuse sisaldus, märgumine 
 Pulbri voolavuse uurimiseks kasutati Helsingi Ülikoolis valmistatud uudset 
seadet, vee sisalduse määramiseks kasutati Karl-Fischeri titrimeetriat. Ana-
lüüsid teostati IND, SOL ja XYL, füüsikaliste segudega ja tahkete disper-
sioonidega. Pulbrite veeauru imamisvõimet/sorptsiooni uuriti mõõtes pulbri 
kõrge niiskuse tingimuste juures (˃90%) säilitamisel tema massi muutust 
ajas Pulbrite hüdrofoobsust ja hüdrofiilsust määrati veetilga kontaktnurga 
määramisel tablettide pinnal. 
‒ Spektroskoopiline analüüs 
 Infrapuna, lähiinfrapuna ja tuumamagnetresontants spektroskoopiat kasutati 
IND, SOL ja XYL, füüsikaliste segude ja tahkete dispersioonide uurimiseks. 
Eesmärk oli uurida toimeainete ja abiainete vahelisi interaktsioone (H-side-
mete teket) ja toimeaine domeeni suurust polümeeri maatriksis. 
‒ Termiline analüüs 
 Diferentsiaalset skaneerivat kalorimeetriat ja termogravimeetrilist analüüsi 
kasutati termiliste sündmuste registreerimiseks, vee sisalduse määramiseks 
ja termilist stabiilsust IND, SOL ja XYL, füüsikalistel segudel ja tahketel 
dispersioonidel. 
‒ Dissolutsioonitestid 
 In vitro test lahustumiskiiruse uurimiseks pH 1.2 ja 6.8 juures viidi läbi IND, 
füüsikaliste segude ja tahkete dispersioonidega. Vabanenud toimeaine kon-
sentratsioonid määrati spektrofotomeetriliselt ja kinnitati kõrgefektiivse-
vedelikkromatograafiaga. 
- Stabiilsustestid 
 Tahkete dispersioonide füüsikaline stabiilsus (kuni kaks kuud) kahe erineva 
abiainega (SOL/XYL) viidi läbi toatemperatuuril kontrollitud niiskuse juures 
(0%, 50%, 90%) valguse eest kaitstult. 
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TULEMUSED JA ARUTELU 
–  Tahkete dispersioonide stabiilsuseuuringud näitasid, et kahefaasiline amorfse 
IND-i ja XYL-i süsteemis toimeaine kristalliseerus peale 4 päeva, kusjuures 
SOL-i sisaldav tahke dispersioon oli stabiilne vähemalt 2 kuud (I). SOL 
sisaldavad süsteemid inhibeerivad toimeaine kristallisatsiooni hoides IND 
amorfsena. Kristalliline XYL soodustab aga amorfse toimeaine kristalli-
satsiooni käitudes kristallisatsiooni pinnana. 
–  Pulbriomaduste uurimine näitas, et füüsikalistes segudes on toimeaine 
kristallid kleepunud abiainete pinnale, agatahketes dispersioonides on nad 
kokku sulanud. Pulbri voolavus sõltus oluliselt abiainete omadustest. Mõle-
mad abiained (SOL/XYL), sõltuvalt kogusest parandasid füüsikaliste segude 
ja tahkete dispersionide voolavust. Füüsikaliste segude ja tahkete disper-
sioonide voolavus statistiliselt ei erinenud (p ˂ 0.05). XYL-i sisaldavad 
segud näitasid paremat märgumist võrreldes vastavate SOL-i sisaldavate 
segudega ja kristallilise IND-ga. Abiained vähendasid ka IND-i ja vastavate 
füüsikaliste segude ning tahkete dispersioonide veetilga kontaktnurka, 
parandades süsteemi hüdrofiilsust. 
–  Sulami-kiirjahutamise meetodil said valmistatud kahefaasilised süsteemid, 
kus SOL-i sisaldavas tahkes dispersioonis oli tegu amorfse IND-ga disper-
geeritud amorfses polümeeri-maatriksis ning XYL-i sisaldavas tahkes disper-
sioonis amorfse IND-ga sadenenud kristallilise suhkru-maatriksis. Mõlemad 
kahefaasilised süsteemid erinevate abinetega näitasid kiiremat toimeaine 
vabanemist võrreldes kristallilise IND-ga. Erandiks oli IND-i ja SOL-i 
füüsikaline segu, millest toimeaine vabanemine oli isegi aeglasem võrreldes 
puhta IND-ga. Põhjuseks võib olla polümeeri geelistumine, mis takistab 
toimeaine vabanemist.  
–  Edukas fiibri valmistamine sulami-elektrospinnimisel oli võimalik tänu vee 
kui plastifikaatori lisamisele. Selleks hoiti IND-i ja SOL-i füüsikaline segu 
kõrge niiskuse (90%) juures enne sulami-elektrospinnimist. Tänu vee ole-
masolule süsteemis õnnestus tööprotsessi temperatuuri langetada ca 40 ˚C. 
Võrdluseks oli valmistatud toimeaine vaba puhas polümeeri fiiber, mida 
samuti hoiti eelnevalt kõrge niiskuse juures (III). 
–  Sulami-elektrospinnimise teel valmistatud fiibrid olid siledad, kurrulise 
pinnaga, ristlõikes täheldati avausi (kanaleid), mis olid tekkinud tänu vee 
arustumisele. Fiibri komponendid IND ja SOL näitasid molekulaarsel tase-
mel efektiivset omavahelist segunevust. HPLC kinnitas minimaalset toime-
aine lagunemist elektrospinnimine ajal, kinnitades seega protsessi stabiilsust. 
Tahke faasi analüüs näitas, et IND on fiibris amorfses vormis. NMR näitas 
ka 25–100 nm suuruseid IND-i domeene tahkes dispersioonis. Vees halvasti 
lahustuva toimeaine lahustumiskiirus fiibrist oli märgatavalt suurem võrrel-
des füüsikaliste segude (kristalliline/amorfne IND + polümeerne abiaine, 
SOL) ja kristallilise IND-ga. Esimese 30 min jooksul vabanes ˃90% toime-
ainest. Antud nähtuse põhjusteks on suurem fiiber-materjali eripind ja 
materjali poorsus ning toimeaine amorfse vormi olemasolu (III). 
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KOKKUVÕTE 
Sulatamise meetodil valmistatud kahefaasilised tahked dispersioonid vees hal-
vasti lahustuva toimeainega (indometatsiin, IND) ja kahe erineva abiainega 
(amorfne kopolümeer vs. kristalliline suhkur alkohol). Mõlemad abiained 
parandavad kohesiivse IND-i pulbri voolavust, mis on otseselt seotud abiaine 
kogusega füüsikalistes segudes või tahketes dispersioonides. Samuti paraneb 
mõlema abiaine (SOL/XYL) ja IND-i segude märguvus, aga XYL-i sisaldavad 
segud omavad kõrgemaid sorptsiooninäitajaid võrreldes SOL-ga. Toimeaine 
vabanemine in vitro tingimustes pH 6.8 juures füüsikalisest ja tahketest dis-
persioonidest sõltus suuresti kasutatavast abiainest. Toimeaine suurem lahustu-
miskiirus SOL-i sisaldavatest tahketest dispersioonidest on seotud parema 
märgumisega ja inhibeeritud IND-i kristallisatsiooniga. Seega on IND tahkes 
dispersioonis amorfses vormis. XYL on vees kergesti lahustuv polüalkohol, mis 
parandab IND-i lahustumiskiirust suure tõenäosusega läbi parema märgumise ja 
hüdrofiilsema keskkonna tekitamise, sest IND ei püsi neis süsteemides 
amorfsena. 
Lisaks sellele, sulami-elektrospinnimine tõestas end uudse võimalusena tah-
kete amorfsete dispersioonide valmistamisemeetodina vees halvasti lahustuvale 
toimeainele. Sulami-kiirjahutamisel ja sulami-elektrospinnimisel toimus ainult 
minimaalne toimeaine (IND-i) termiline lagunemine. Sulami-elektrospinnimise 
fiibri tahke-faasi analüüs näitab IND-i ja amorfse stabiliseeriva SOL-i moleku-
laarsel tasemel homogeenset segu. Sulami-elektrospinnimisel valmistatud IND-i 
ja SOL-i fiiber näitasid kiiremat lahustumist kui vastavad sulami kiirjahutamise 
meetodil valmistatud tahked dispersioonid, füüsikalised segud ja kristalliline 
toimeaine. Kokkuvõteks, sulami-elektrospinnimist võib käsitleda alternatiivse 
meetodina traditsioonilisele või modifitseeritud sulami-kiirjahutamisele ja sulami 
ekstrusioonile, mis võimaldab valmistada amorfseid tahkeid dispersioone ja 
parandada seega toimeaine lahustumiskiirust ja seega vees halvasti lahustuvate 
toimeainete biosaadavust. Antud töö vajab edasist uurimist, kinnitamaks kas 
antud tulemused väljenduvad paremas absorptsioonis ja biosaadavuses in vivo 
uuringutes 
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